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Abstract 
 
Alpha2-agonists are a class of drugs widely used in veterinary anaesthesia; moreover by means 
of their action on adrenoceptors that are widespread distributed in several tissues, they can be 
beneficial for different clinical applications. The aim of this work was to describe new applications 
of alpha2-agonists in veterinary medicine. 
In cats, high dose medetomidine is administered to perform semen collection by urethral 
catheterization. We have investigated the haemodynamic effects of high dose medetomidine (0.13 
mg kg-1) administered to healthy male cats. Haemodynamic evaluations were performed before and 
after medetomidine administration and consisted of: clinical examination, blood pressure evaluation 
and transthoracic echocardiography. Significant hemodynamic alterations were observed, even if 
they were similar to that provided by lower dosages. The cats recovered without clinical alterations. 
Despite their cardiovascular side effects, low doses of alpha2-agonists can be beneficial for the 
maintenance of a good cardiovascular stability for specific conditions.  
In humans, dexmedetomidine helps in maintaining a good hemodynamic stability if administered 
for pheochromocytoma ablation. We have described the administration of dexmedetomidine for the 
anesthetic management of two dogs with a suspicion of pheochromocytoma undergoing 
adrenalectomy. Dogs received dexmedetomidine intramuscularly (0.001 mg kg-1) and 
dexmedetomidine and remifentanil were administered (0.0005 mg kg-1h-1 and 0.0003 mg kg-1min-1, 
respectively) throughout the surgery. In this study dexmedetomidine infusion together with 
remifentanil provided satisfactory intraoperative anesthetic and hemodynamic control in two dogs 
with a suspicion of pheochromocytoma. 
 In patients undergoing craniotomy, dexmedetomidine, increasing the cerebral vascular 
resistance, prevents alteration of the cerebral blood flow. We have described the administration of 
dexmedetomidine in five Macaca fascicularis undergoing craniotomy for physiologic research. The 
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Macaca were sedated with ketamine (8 mg kg-1) and dexmedetomidine (0.02 mg kg-1) 
intramuscularly. Dexmedetomidine was administered by infusion (0.012 mg kg-1h-1) throughout the 
procedure and provided adequate analgesia and a stable hemodynamic control in healthy Macaca. 
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Riassunto 
 
I farmaci alfa2-agonisti sono largamente utilizzati in anestesia veterinaria; inoltre, grazie alla loro 
azione sui recettori alpha-adrenergici, distribuiti in diversi tessuti, sono utilizzati per diverse 
applicazioni cliniche. L’obiettivo del presente studio è stato quello di descrivere nuove applicazioni 
degli alfa2-agonisti in medicina veterinaria. 
Nel gatto, la medetomidina somministrata ad alte dosi consente la raccolta del seme mediante 
cateterismo uretrale. Abbiamo valutato gli effetti emodinamici della medetomidina somministrata al 
dosaggio di 0.13 mg kg-1 in gatti sani. Le valutazione emodinamiche sono state eseguite prima e dopo 
la somministrazione di medetomidina mediante visita clinica, misurazione della pressione sistemica 
ed ecocardiografia transtoracica. Dallo studio sono state evidenziate alterazioni emodinamiche 
significative, ma simili a quelle riportate dopo somministrazione di dosi più basse.  
I farmaci alpha2-agonisti, nonostante le alterazioni cardiovascolari che inducono, se 
somministrati a basse dosi, possono contribuire al mantenimento di una buona stabilità emodinamica 
in condizioni cliniche specifiche.  
Nell’uomo, la somministrazione di dexmedetomidina in pazienti sottoposti a rimozione di un 
feocromocitoma contribuisce a mantenere parametri emodinamici intraoperatori stabili. Abbiamo 
descritto la somministrazione perioperatoria di dexmedetomidina in due cani sottoposti a 
surrenalectomia per un sospetto di feocromocitoma. Entrambi hanno ricevuto dexmedetomidina 
intramuscolo (0.001 mg kg-1) e dexmedetomidina e remifentanil sono stati somministrati in infusione 
(0.0005 mg kg-1h-1 e 0.0003 mg kg-1min-1, rispettivamente) per tutta la chirurgia. Il protocollo 
utilizzata ha permesso di mantenere un piano anestesiologico e condizioni emodinamiche stabili in 
due cani con sospetto di feocromocitoma. 
Nei pazienti sottoposti a neurochirurgia, la dexmedetomidina previene alterazioni significative 
del flusso cerebrale. Abbiamo descritto la somministrazione di dexmedetomidina in esemplari di 
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Macaca fascicularis sottoposti a craniotomia. I macachi sono stati sedati con ketamina e 
dexmedetomidina. La dexmedetomidina è stata somministrata in infusione continua (0.012 mg kg-1h-
1) per tutta la procedura e ha permesso di mantenere un’analgesia adeguata e parametri emodinamici 
stabili in macachi sani.  
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Alpha2-adrenoceptor agonists in veterinary medicine 
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Introduction 
 
Alpha2-adrenoceptor agonists are a class of drugs widely used in veterinary anesthesia to obtain 
sedation, analgesia and muscle relaxation. Their application has been described in small companion 
animals (Sinclair et al. 2003; Lemke 2004), in large animals (Daunt and Steffey, 2002; Valverde 
2010; Gozalo-Marcilla et al. 2015) and in laboratory animals (Lee et al. 2010; Lugo-roman et al. 
2010) among others.  
The alpha2-adrenoceptor drugs most commonly used in clinical practice are xylazine, 
detomidine, romifidine, medetomidine and dexmedetomidine.  
Xylazine was first synthesized in Germany in 1962 as an antihypertensive drug but its sedative 
properties were soon discovered in animals, becoming the first alpha2-agonist used in veterinary 
anesthesia. It was first used in ruminants, then in horses and cats (since 1970s), and finally in dogs 
(Green and Thurmon 1988; Paddleford and Harvey 1999). 
The administration of alpha2-agonists also produces side effects which must be taken into 
consideration. A decrease in heart rate and arrhythmias, and a biphasic pressure response are the most 
problematic side effects described after alpha2-agonist administration at therapeutic doses. In 
addition, several endocrine effects have been recognized: decreased insulin release, glycogenolytic 
effects and decreased antidiuretic hormone release.    
Since alpha2 adrenoceptors are involved in the regulation of several physiological mechanisms, 
their administration may provide multiple effects other than those sedative and analgesic.  
Among other applications, studies in veterinary medicine have reported their administration in 
male animals of several species for semen collection. In cats, high doses of medetomidine (0.13 mg 
kg-1) are needed to obtain semen release into the urethra. Since the effects of high dose medetomidine 
in cats have never been described, the aim of this study was to investigate the hemodynamic effects 
induced by medetomidine administered intramuscularly in healthy cats at a dose of 0.13 mg kg-1.  
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In addition, dexmedetomidine administration has been reported to improve cardiovascular 
stability in human patients with pheochromocytoma and in those undergoing pheochromocytoma 
ablation. In dogs, adrenalectomy is the treatment of choice for patients with pheochromocytomas; 
however, mortality is high due to catecholamine release during mass manipulation. Alpha2-agonists 
have been described to reduce the catecholamine release; therefore, one of the following studies 
described the use of dexmedetomidine infusion as an adjunct to a balanced anesthetic protocol in two 
dogs undergoing pheochromocytoma ablation.   
Finally, dexmedetomidine has been described as a potential supplemental anesthetic drug in 
human patients undergoing intracranial surgery. To the best of our knowledge, there are no studies 
evaluating the use of dexmedetomidine as an adjunct for the anesthetic management of veterinary 
patients undergoing craniotomy. Therefore, we aimed to describe the use of dexmedetomidine 
administered by continuous rate infusion (CRI) for the anesthetic management of Cynomolgus 
monkeies used as animal models and undergoing craniotomy for the purpose of physiologic research. 
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Mechanism of action of alpha2-adrenoceptor agonists 
Alpha2-agonists exert their action by means of agonism on the alpha2-adrenoceptors. In addition, 
the majority of them, except for xylazine, have an imidazoline ring and can be combined with 
imidazoline receptors (Khan et al. 1999; Clarke et al. 2014). 
 
Alpha- adrenoceptors 
Alpha-adrenoceptors are differentiated on the basis of their sensitivity to agonists and antagonists 
(Table 1). Alpha2-adrenoceptors are located presynaptically and postsynaptically in both central and 
peripheral sites while alpha1-adrenoceptors are only postsynaptic. Norepinephrine (NA) is the natural 
ligand for both alpha1- and alpha2-adrenoceptors; when NA is released from a sympathetic neuron, it 
acts on both receptors inducing sympathetic stimulation. When activated, presynaptic alpha2-
adrenoceptors exert a negative feedback and prevent the additional release of NA, decreasing the 
sympathetic outflow from the central nervous system (CNS) (Figure 1). Postsynaptic alpha1 and 
alpha2-adrenoceptors usually exert a stimulating effect. 
Alpha2-adrenoceptors are transmembrane receptors formed by a long chain of amino acids with 
hydrophilic and hydrophobic areas which cross the cell membrane seven times (Khan et al. 1999). 
Alpha2-adrenoceptors belong to the family of guanine nucleotide-binding proteins (G-proteins)-
coupled receptors. G-proteins are formed by alpha, beta and gamma subunits, and have been 
identified on the intracellular side of the cell membrane. The alpha subunit at rest binds to guanosine 
diphosphate (GDP). When the receptor is activated by its agonist, it changes its structure binding with 
the G-protein which reduces its affinity for GDP and, in the presence of magnesium, it becomes 
guanosine triphosphate (GTP). The alpha subunit leaves the G-protein, reaching the effector and, 
concurrently, the agonist leaves the receptor (Figure 2). The GTPase, which is now activated, 
hydrolyzes GTP to GDP with the release of an inorganic phosphate, and the receptor becomes inactive 
(Taylor 1990; Khan et al. 1999).  
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Alpha2-adrenoceptors are involved in more than one effector mechanism. Their activation 
through the inhibitory G-protein (Gi-protein) inhibits the adenylyl cyclase, resulting in the decreased 
formation of 3',5'-cyclic adenosine monophosphate (cAMP), the second messenger of many 
biological mechanisms (Khan et al. 1999). The activation of the stimulatory G-protein (Gs- protein) 
causes hyperpolarization of the neuronal cells. However, other studies have suggested that the effect 
resulting from the activation of alpha2-adrenoceptors depends only on the agonist concentration; a 
low alpha2-agonist concentration results in the inhibition of cAMP while high agonist concentration 
induces an increase in cAMP (Eason et al. 1992; Gyires et al. 2009).  
An alternative mechanism involves voltage-gated calcium ion channels coupled to a G-protein; 
this theory states that the decrease in calcium ion conductance results in the inhibition of the 
neurotransmitter release (Khan et al. 1999). 
The presynaptic alpha2-adrenoceptors involved in the inhibition of the NA release are mainly 
located in sympathetic nerve endings and in non-adrenergic neurons in the CNS. Postsynaptic alpha2-
adrenoceptors have been identified in several tissues, such as the liver, pancreas, platelets, kidney, 
adipose tissue and the eye, where they are involved in several physiologic functions (Khan et al. 
1999).  
Four alpha2-adrenoceptor subtypes have been identified on the basis of pharmacological and 
molecular studies: alpha2A, alpha2B, and alpha2C. The fourth type, alpha2D, identified in the rat brain 
is the homologue of human alpha2A.  
In the CNS, the alpha2A-subtype has been identified in the brain and mainly in the locus ceruleus, 
the alpha2B-subtype has been found only in the thalamus and the alpha2C-subtype is widely distributed 
but is mainly present in the basal ganglia (MacDonald and Scheinin 1995). Radioligand binding 
assays and real time polymerase chain reaction (PCR) have confirmed the presence of the alpha2A-
adrenoceptor subtype in the dog brainstem (Schwartz et al. 1999). 
The most commonly used alpha2-agonists are characterized by a different selectivity towards the 
alpha1- and the alpha2 adreceptors (Table 2). This difference in selectivity towards alpha-
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adrenoceptors explains the differences in the sedative and physiologic effects obtained with their 
administrtaion. Schwartz and Clark (1998) evaluated the affinity of xylazine, detomidine and 
medetomidine for the different adrenoceptor subtypes. They found that detomidine and medetomidine 
have a higher affinity for all receptors when compared to xylazine.  
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Receptor type Specific drug Action 
Alpha1-adrenoceptors Epinephrine 
Agonist 
Norepinephrine 
Phenylephrine 
Methoxamine 
Prazosin Antagonist 
Alpha2-adrenoceptors Epinephrine 
Agonist Norepinephrine 
Clonidine 
Yohimbine Antagonist 
 
Table 1-Classification of alpha-adrenoceptors based on their sensitivity for agonists and 
antagonists (Clarke et al. 2014) 
Drug Selectivity alpha2: alpha1 receptors 
Xylazine 160:1 
Detomidine 260:1 
Romifidine 340:1 
Medetomidine 1620:1 
Dexmedetomidine 1620:1 
 
Table 2- alpha2: alpha1 receptor selectivity (Khan et al. 1999; Muir 2009) 
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Figure 1-Mechanism of action of the alpha1 and alpha2 adrenoceptors (Clarke et al. 2014) 
 
 
 
 
Figure 2- Receptor interaction with the G-protein (Taylor 1990) 
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Imidazole receptors 
On the cell membranes, imidazoline receptors are always associated with alpha2-adrenoceptors 
with the unique exception of chromaffin cells (Farsang and Kaposci 1999).   
Three subtypes of imidazoline receptors have been identified:  
• I1 receptors have been identified on the cell membranes in the ventrolateral medulla, in the 
cortex and in other regions of the brain. They have also been described outside the brain on 
chromaffin cells, on platelets and in the glomus caroticum (Farsang and Kaposci 1999). I1 receptors 
are involved in blood pressure regulations; their activation induces hypotension. 
• I2 receptors have been localized on the outer side of the mitochondrial membrane. I2 receptors 
have been identified mainly in the brain (in the cortex and in the nucleus striatum) but also in several 
viscera: the pancreas, prostate, urethra, placenta, kidney, colon, endothelial cells, glomus caroticum, 
adrenal medulla, platelets and adipocytes (Farsang and Kaposci 1999; Khan et al. 1999).   
• Not I1-Not I2 receptors have been identified on the axon terminal of the sympathetic neurons. 
In rabbits, these receptors have been described in the aorta, pulmonary artery, heart and iris;  in rats 
they have been identified in the lungs and in the kidneis (Farsang and Kaposci 1999). The endogenous 
ligands of imidazoline receptors are: clonidine displacing substance (CDS), immunoreactive CDS 
and agmatine, involved in the regulation of several biological effects (Farsang and Kaposci 1999).  
The mechanism of action of imidazoline receptors has not yet been clarified. Authors have 
hypothesized that the I1 receptor is coupled with a G-protein and activates choline phospholipid 
hydrolysis with the subsequent formation of products, such as diacylglyceride, arachidonic acid, 
prostaglandin and eicosanoids (Ernsberger et al. 1995; Ernsberger 1999; Farsang and Kapocsi 1999). 
Moreover, the activation of this receptor inhibits the Na+/H+ exchange and is involved in the 
activation of enzymes for catecholamines (Ernsberger 1999).  The I2 receptor does not seem to be 
linked to a G-protein but, instead, to be coupled with a potassium channel (Okumara et al. 1992). 
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The imidazoline receptors are not involved in sedation; however, due to their widespread 
distribution, they regulate several mechanisms. They control catecholamine synthesis in the adrenal 
medulla, they modulate blood pressure and intraocular pressure, and they are involved in the 
modulation of glucose metabolism and body temperature (Ernsberger et al. 1995; Farsang and 
Kapocsi 1999). Central imidazole receptors have been demonstrated to be involved in the hypotensive 
and anti-arrhythmic effects mediated by clonidine and dexmedetomidine, respectively (Kamibayashi 
et al. 1995). 
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Sedative effects 
The alpha2-adrenoceptor agonists are widely used in veterinary medicine to obtain sedation and 
anxiolysis. Alpha2-agonist binding with alpha2A-adrenoceptors located in the locus coeruleus 
prevents additional NA release with subsequent sedation (Sinclair 2003). 
 A study in rats has demonstrated that dexmedetomidine administration into the locus coeruleus 
induces sedation in a dose-dependent manner which is mediated by alpha2-adrenoceptors. In fact, this 
hypnotic effect was reversed by the systemic administration of an alpha2-adrenoceptor antagonists, 
such as atipamezole, which crossed the blood brain barrier (Correa-Sales et al. 1992). Instead, the 
administration of alpha1- or beta- adrenoceptor antagonists did not reverse the sedation (Doze et al. 
1989).  
The alpha2-agonists most commonly used for sedation in dogs, cats and horses are xylazine, 
detomidine, romifidine, medetomidine and dexmedetomidine. They can be used alone or in 
combination with an opioid to improve the quality of sedation.  
Alpha2-agonists are also commonly administered by constant rate infusion (CRI) as part of 
balanced anesthetic protocols in several species (Bettschart-Wolfensberger et al. 2001; Carter et al. 
2010; Pypendop et al. 2011; Pascoe 2015). Their intraoperative administration has been proven to 
reduce the mean alveolar concentration (MAC) of inhalant anesthetics, or the dose of propofol or 
alfaxalone required for the maintenance of a stable anesthetic plane (Ewing et al. 1993; Neges et al. 
2003; Ringer et al. 2007). In equine anesthesia, the adjuncts of alpha2-agonists by CRI to a balanced 
anesthetic protocol assure a better quality of recovery as well as a stable anesthetic plane (Ringer et 
al. 2007; Gozalo-Marcilla et al. 2015). In horses, the sedative effects observed after alpha2-agonist 
administration are decreased awareness, drop of the head, ptosis of the eyelids and of the lower lip, 
and ataxia (Valverde 2010). 
 
Xylazine 
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Xylazine has been used in clinical practice since the 1960s. It does not have any imidazole ring 
and, therefore, it does not act on imidazole receptors (Clarke et al. 2014).  
Xylazine provides a rapid onset of sedation after intramuscular (IM) and intravenous (IV) 
administration, while subcutaneous administration (SC) is less reliable and provides only poor 
sedation (Clarke et al. 2014; Rankin 2015).  
In horses, xylazine is used to obtain sedation for standing procedures or as a premedicant drug 
before the induction of general anesthesia (Green and Thurmon 1988; Ringer et al. 2013; Rankin 
2015). Suggested doses for this species are 0.5-1.0 mg kg-1 and 1.0-2.0 mg kg-1 for the IV and IM 
routes, respectively. Xylazine administered to horses at 1.1 mg kg-1 provides deep sedation and 
analgesia within 5-10 minutes, lasting 30-60 minutes and with an elimination half-life of 
approximately 50 minutes (Garcia-Villar et al. 1981; Jochle et al. 1991; Rankin 2015). The 
combination of xylazine, ketamine and guaifenesin (also known as triple drip) has been described for 
the maintenance of intravenous general anesthesia in horses. This protocol has been recommended 
only for procedures lasting less than 1 hour (Davidson 2008). 
Cattle are particularly sensitive to xylazine, especially the Brahman breed; lower initial doses 
should be used in these cattle for sedation (Green and Thurmon 1988). In this species, deaths have 
been reported from hypoxemia after xylazine administration (Clarke et al. 2014). In cattle, xylazine 
0.2 mg kg-1 reached its peak plasma concentration 15 minutes after IM administration and had an 
elimination half-life of 30 minutes (Garcia-Villar et al. 1981). 
In dogs and cats, xylazine has been used for short-term sedation to perform diagnostic procedures 
or as a premedicant agent prior to general anesthesia (Green and Thurmon 1988; Paddlerford and 
Harvey 1999). The recommended dose of xylazine in dogs and cats ranges from 0.25 to 0.5 mg kg-1 
IV and 0.5 to 1.0 mg kg-1 IM. In dogs, xylazine 1.4 mg kg-1 administered IM reached its peak plasma 
concentration after 15 minutes and had an elimination half-life of 30 minutes (Garcia-Villar et al. 
1981). Xylazine has recently been described in association with ketamine in dogs to provide smooth, 
safe and effective total intravenous anesthesia (TIVA) for minor procedures (Ibrahim 2017). The 
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combination of ketamine (2 mg kg-1 IV for induction followed by an infusion of 10 mg kg-1 h-1) in 
combination with xylazine (1 mg kg-1 IV followed by 1 mg kg-1 h-1) provided a stable anesthetic plane 
for 60 minutes characterized by smooth induction and recovery, and good muscle relaxation without 
any paddling or tonic-clonic movement. The animals were able to stand 36 minutes after the 
disconnection of 60 minutes of anesthesia infusion (Ibrahim 2017). 
 
Detomidine 
Detomidine is more commonly used in horses and cattles than in small animals, and its potency 
has been shown to be similar among several species (Clarke et al. 2014). Detomidine is more potent 
than xylazine, and effective sedation can be achieved with lower doses; however, it has a wide 
therapeutic index (Rankin 2015). 
In horses, detomidine can be used as a premedicant drug before general anesthesia but is more 
commonly used as a sedative agent for standing procedures. Conversely when either detomidine 
(0.005 mg kg-1 h-1) or saline solution were administered by CRI in isoflurane-anesthetized horses, the 
authors did not find any differences in isoflurane requirement and quality of recovery between the 
two groups (Schauvliege et al. 2011). For standing procedures, even after high doses of detomidine, 
horses maintain the standing position with lower ataxia as compared with sedation provided by other 
alpha2-agonists (Clarke et al. 2014). In horses, detomidine given IV at 0.04 mg kg-1 has a median 
half-life of 26 minutes (Hubbell et al. 2009; Rankin 2015). If the same dose is given to horses soon 
after exercise, the median half-life and the median volume of distribution increase significantly. This 
difference is mainly due to a different distribution of the cardiac output observed after exercise 
(Hubbell et al. 2009). These results might explain why higher dosages are necessary to obtain 
effective sedation in horses after exercise.  
For more invasive standing procedures, such as laparoscopy or dental procedures, detomidine 
administered by CRI alone or in association with opioids has been reported to provide effective 
sedation and analgesia (Cruz et al. 2004; Virgin et al. 2010; Potter et al. 2016). Potter and colleagues 
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have described a protocol for standing dental procedures using acepromazine (0.02 mg kg-1) and 
detomidine 0.01 mg kg-1 followed by detomidine CRI 0.0006 mg kg-1 min-1 in combination with either 
buprenorphine (0.01 mg kg-1) or morphine (0.1 mg kg-1). Both protocols provided effective sedation 
with the horses receiving buprenorphine having a higher sedation score and a higher incidence of side 
effects in the postoperative period (box walking, abdominal pain and shivering) (Potter et al. 2016). 
The concurrent administration of methadone (0.2 mg kg-1) as an adjunct to low doses of detomidine 
(0.0025 mg kg-1) did not provide more sedation than that observed after the administration of 
detomidine alone (0.005 mg kg-1) (Gozalo-Marcilla et al. 2017). A higher degree of sedation was 
observed when methadone was administered with higher doses of detomidine (0.01 mg kg-1), with 
the peak of the sedative effect observed 15 minutes after administration.  
In ruminants, detomidine provided a more potent sedation when compared to xylazine but has 
been used to a lesser extent. In this species, it provides sedation similar to that provided in horses 
(Riebold 2015). 
In both calves and horses, the sublingual administration of an oro-mucosal gel formulation of 
detomidine has been described (Kaukinen et al. 2011; Hokkanen et al. 2014). In horses, detomidine 
gel administered at a dose of 0.04 mg kg-1 induced sedation within 40 min. In 54% of the horses 
receiving oral detomidine, the sedation was scored moderate to heavy while in 41% of the horses, 
only mild sedation was obtained (Gardner et al. 2010).  In calves, detomidine gel has a bioavailability 
of 34%, and a sublingual dose of 0.08 mg kg-1 has provided effective sedation similar to that obtained 
with the IV administration of detomidine 0.01 mg kg-1 (Hokkanen et al. 2014). 
 
Romifidine 
Romifidine is widely used in horses, and it is labelled for use in this species in several countries. 
However, its use has also been described in small animals (Muir and Gadawski 2002; Selmi et al. 
2002). 
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In horses, romifidine (0.08-0.12 mg kg-1) produces profound sedation for standing procedures 
with less ataxia as compared with other alpha2-agonists (Clarke et al. 2014; Rankin 2015). A study 
has reported that only one out of ten horses stumbled or fell forward 5 minutes after the administration 
of romifidine 0.08 or 0.12 mg kg-1 (Freeman and England 2000). In this species, romifidine is 
commonly used as a premedicant agent but it is also administered by CRI during general anesthesia. 
Wojtasiak-Wypart and colleagues (2012) have reported that, when romifidine was administered 
IV to horses at 0.08 mg kg-1, peak sedation occurred within 15 minutes, and the sedative effect lasted 
up to 2 hours, with an elimination half-life of 138 minutes.  
More recently we have described the partitioning of romifidine in red blood cells after IV 
administration at a dose of 0.1 mg kg-1 (Romagnoli et al. 2017). The Authors found that, after IV 
administration, romifidine concentration in the red blood cells was two times higher than that in the 
plasma, and that the ratio between the two concentrations was constant over time (Figure 3). 
Romifidine has been detected in red blood cells up to 180 minutes after IV injection. This effect is 
explained by the lipophilicity of this drug; it can pass the membrane of the red blood cells binding to 
the membrane or to the intracellular molecules; as soon as the plasma concentration decreases, the 
drug is slowly released from the cells. The plasma concentration of romifidine has been found to be 
higher than 10 mg ml-1 in 75% of the animals included in the study from 30 to 180 minutes after IV 
administration. The Authors have reported that romifidine (0.1 mg kg-1) provided good sedation in 
all horses from 2 minutes after administration, lasting up to 105 minutes; however, half of the horses 
included were still sedated 120 minutes after injection and one horse up to 150 minutes. The Authors 
have hypothesized that romifidine partitioning in the red blood cells could explain the long-lasting 
sedative effect observed in horses after its administration (Romagnoli et al. 2017). In the same study, 
the mean clearance was 22.16 ± 6.67 ml min-1 kg-1, and the mean half-life of distribution and 
elimination was 119.28 (range 51.6-248.9) minutes. 
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Figure 3- Plasma and red blood cells concentration of romifidine and sedation score versus time 
observed in 8 horses after intravenous administration of romifidine 0.1 mg kg-1 (from 
Romagnoli N, Al-Qudah KM, Armorini S, Lambertini C, Zaghini A, Spadari A, Roncada P (2017) 
Pharmacokinetic profile and partitioning in red blood cells of romifidine after single intravenous 
administration in the horse. Vet Med Sci 3, 187-197) 
 
There is some discrepancy among studies concerning romifidine sparing effects on inhalant 
anesthetics. In isoflurane-anesthetized horses, romifidine, administered by CRI at 0.04 mg kg-1 h-1 
(following a bolus of romifidine 0.08 mg kg-1 IV), has been shown to provide an isoflurane sparing 
effect of 15% as compared to horses premedicated with xylazine (1 mg kg-1) and receiving saline 
solution by CRI during surgery (Niimura Del Barrio et al. 2017). In the same study, romifidine 
infusion did not significantly alter the duration or the quality of recovery as compared with the control 
group. However, a previous study, in which an equal dose of romifidine was administered to 
isoflurane-anesthetized horses, had failed to find any sparing effects (Devisscher et al. 2010). The 
differences among the studies may have been due to the fact that different surgical procedures were 
performed on the horses involved.  
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In dogs, romifidine (0.01-0.08 mg kg-1) has been reported to produce effective sedation and a 
sparing effect on the dose of propofol necessary for the induction of general anesthesia (Lemke 1999, 
England et al. 1996; Gomez-Villamandos et al. 2005) 
 
Medetomidine  
Medetomidine is a racemic mixture, widely used in both small and large animals (Bryant et al. 
1991; Sinclair 2003; Ringer et al. 2007). 
In horses, medetomidine (0.007 mg kg-1) produced more ataxia with respect to other alpha2-
agonists up to recumbency (Bryant et al. 1991; Bettschart-Wolfensberger et al. 1999). For this reason, 
and due to its short duration of action, it is not commonly used for standing procedures but more often 
for premedication followed by CRI during general anesthesia (Ringer et al. 2007; Clarke et al. 2014). 
Its intraoperative administration, in horses anesthetized with isoflurane, helps in maintaining a stable 
anesthetic plane, reducing the inhalant anesthetic requirement as well as having a good cardiovascular 
stability (Bettschart-Wolfensberger et al. 1999, 2001). Of the other alpha2-agonists, medetomidine 
has the shortest half-life and the most rapid clearance rate. In horses, when medetomidine was 
administered IV as a single bolus (0.007 mg kg-1), its mean elimination half-life was 51.3 min and its 
total body clearance was 4.0 ml kg-1 h-1 (Bettschart-Wolfensberger et al. 1999). In the same species, 
medetomidine (0.01 mg kg-1,) reaches peak plasma concentration 6.4 minutes after IV administration, 
with an elimination half-life of 29 minutes (Grimsrud et al. 2012). 
In small animals, medetomidine has been used as a single bolus for sedation or as CRI during 
general anesthesia. In dogs, doses of 0.03 mg kg-1 have been reported to provide similar sedation to 
xylazine 2.2 mg kg-1(Cullen 1996; Vainio et al. 1989). In the same species, medetomidine 0.04 mg 
kg-1 administered IV provided sedation in 15-20 minutes corresponding to a plasma concentration of 
18.5 ng ml-1 (Kuusela et al. 2000). The administration of a low dose CRI of medetomidine (0.1 mg 
kg-1 h-1) as part of a balanced anesthetic protocol contributed to the maintenance of a stable anesthetic 
plane and provided effective analgesia in dogs undergoing ovariohysterectomy (Rioja et al. 2013). 
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The more commonly used dosages suggested in clinical practice for obtaining effective sedation in 
dogs range from 0.02 to 0.15 mg kg-1; the duration of the sedative effect is dose dependent (Stenberg 
et al. 1987). 
In cats, medetomidine is commonly combined with ketamine or opioids to achieve effective 
sedation (Slingsby et al. 2015). The combination of medetomidine (0.03 mg kg-1) with buprenorphine 
(0.02 mg kg-1) has been reported to significantly reduce the amount of inhalant anesthetic required 
for maintenance of general anesthesia as compared with medetomidine alone (Grint et al. 2009). The 
addition of medetomidine (0.02 mg kg-1) to butorphanol (0.2 mg kg-1) has been reported to be more 
effective than the addition of acepromazine (0.2 mg kg-1) in reducing the dose of alfaxalone necessary 
for the induction and maintenance of general anesthesia (Schwarz et al. 2014).  
 
Dexmedetomidine 
Dexmedetomidine is the D-isomer of medetomidine and has a selectivity alpha2:alpha1 ratio of 
1300:1 and an alpha2:imidazoline selectivity ratio of 32:1 (Khan et al. 1999). Dexmedetomidine, 
administered at half the dose of medetomidine, has been reported to provide similar effects (Kuusela 
et al. 2000; Bettschart-Wolfensberger et al. 2005).  
In horses, dexmedetomidine has a rapid distribution and a short duration of action. For this 
reason, in this species, it is administered by CRI as part of a balanced anesthetic protocol in order to 
provide a constant level of sedation and to improve the recovery quality (Bettschart-Wolfensberger 
et al. 2005; Marcilla et al. 2012; Marly-Voquer et al. 2016). In equine species, its half-life of 
elimination, after a single bolus (0.0035 mg kg-1), is 28.96 ± 7.61 minutes (Bettschart-Wolfensberger 
et al. 2005). 
In dogs, dexmedetomidine (0.02 mg kg-1) provides similar sedation to that obtained with the 
administration of medetomidine (0.04 mg kg-1) but with a longer lasting effect (Kuusela et al. 2000). 
The concurrent administration of levomedetomidine (0.01-0.02 mg kg-1) did not provide any 
adjunctive effect to the sedation obtained with dexmedetomidine alone. Conversely, higher doses of 
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levomedetomidine (0.08 mg kg-1) reduced the sedative and analgesic effects of dexmedetomidine 
when administered together (Kuusela et al. 2000, 2001).  In dogs sedated with dexmedetomidine 
(0.01 and 0.02 mg kg-1), the peak sedative effect was obtained 10 to 20 minutes after IV 
administration, corresponding to a plasma concentration of 5.5± 3.0 and 14.0 ± 4.5 ng ml-1, 
respectively (Kuusela et al. 2000). Dexmedetomidine, administered as a CRI (0.0015 mg kg-1 h-1 and 
0.0045 mg kg-1 h-1) in sevoflurane-anesthetized dogs produced a dose-dependent decrease in the 
MAC of the inhalant anesthetic (Hector et al. 2017). 
In cats, dexmedetomidine (0.01 mg kg-1) has been used alone to obtain effective sedation, even 
if the addition of opioids or ketamine provided more adequate sedation without increasing the 
incidence of adverse cardiovascular effects. In particular, its combination with butorphanol (0.2 mg 
kg-1) decreased the incidence of vomiting (Bhalla et al. 2017). When dexmedetomidine, at doses of 
0.02-0.04 mg kg-1, was combined with alfaxalone (5 mg kg-1), general anesthesia was obtained (Selmi 
et al. 2003; Rodrigo-Mocholí et al. 2016). Dexmedetomidine administered to cats as a premedicant 
drug before general anesthesia significantly reduced the dosage of the induction agent and the MAC 
of isoflurane in a plasma concentration related manner (from 0.006 to 11.46 ng ml-1) (Escobar et al. 
2012; McSweeney et al. 2012). Dexmedetomidine administered at a dose of 0.025 mg kg-1 reached 
its peak plasmatic concentration (10.2 ng ml-1) 17.8 minutes (range 2.6- 44.9) after IM administration 
(Pypendop et al. 2017). 
The oral administration (PO) of dexmedetomidine has been described in humans and small 
animal practice. In dogs dexmedetomidine is well absorbed systemically through the oral mucous 
membrane and this method of administration was effective for the sedation of fractious and fearful 
dogs (Cohen and Bennett 2015). In cats, the oral or the IM administration of dexmedetomidine has 
similar systemic bioavailability with comparable sedative and antinociceptive effects (Slingsby et al. 
2009). 
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Analgesic effects 
The analgesic effect of alpha2-agonists is the result of their action at the central and spinal levels. 
At the spinal level, they bind to alpha2A, alpha2B and alpha2C receptors in the dorsal horn of the spinal 
cord. The activation of noradrenergic receptors inhibits the NA and the substance P release from Ad 
and C fibers, thereby inhibiting the central transmission of the afferent nociceptive stimuli (Valverde 
2010). In both the brain and the spinal cord, the alpha2-adrenoceptors interact with the opioid 
receptors and share the same signal transduction system, the G protein. Opioid inhibition of 
nociceptive transmission at the spinal level might be mediated by the activation of the alpha2-
adrenoceptors. Among opioid receptors, the d-subtype has been found to be the main subtype 
involved in interaction with the adrenergic receptors (Omote et al. 1991). Studies support the 
interaction between alpha2-adrenergic receptors and opioid receptors. For example, Ossipov and 
colleagues (1989) have demonstrated that systemic yohimbine attenuates the nociceptive effect of 
intrathecally-administered morphine and clonidine.  
Studies have suggested that the analgesic effect of alpha2-agonists is dose dependent but shorter 
lasting when compared to the sedative effect (Kramer et al. 1996). The analgesia provided by these 
drugs, even when locally administered, is reversed by the administration of the specific antagonist 
(Sabbe et al. 1994; Sinclair 2003). 
 
Systemic administration 
The effect of the systemic administration of alpha2-agonists has been evaluated on both somatic 
and visceral nociception. Their application has been described in clinical trials and in experimental 
models applying thermal and mechanical thresholds, or duodenal and colorectal distension for 
somatic and visceral evaluation respectively. The results change with species and the drugs used, and 
also depend on the stimulus applied. 
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In horses, xylazine has been used to provide sedation and analgesia since it was first introduced 
in veterinary practice (Daunt and Steffey 2002). The analgesic effect of xylazine has been compared 
to opioids in a model of visceral analgesia in which colic was experimentally induced by inflating a 
balloon in the cecum (Muir and Robertson 1985). In that study xylazine (1.1 mg kg-1) provided a 
more effective and longer lasting analgesia as compared with that provided by butorphanol (0.2 mg 
kg-1), meperidine (1.0 mg kg-1) and penthazocine (0.99 mg kg-1). In another study regarding the same 
species, the combination of xylazine with opioids (morphine, butorphanol or nalbuphine) did not 
provide any adjunctive analgesia for dental dolorimetry as compared to xylazine administered alone 
(Brunson and Majors 1987). When xylazine was combined with butorphanol it potentiated its 
analgesic effect up to 30 to 60 minute after administration (Brunson and Majors 1987).  
In a clinical study on horses with signs of colic, detomidine (0.020 and 0.040 mg kg-1) has been 
used to relieve abdominal pain and was more effective in decreasing signs of pain than xylazine (0.5 
mg kg-1), but also compared to butorphanol (0.1 mg kg-1) and flunixin meglumine (1.0 mg kg-1) 
(Jochle et al. 1989). In the same species, an experimental study has been reported that detomidine 
(0.010 and 0.020 mg kg-1) significantly increased the colorectal and duodenal distension threshold 
without affecting the thermal threshold (Elfenbein et al. 2009).  
Alpha2-agonists have also been used to relieve pain in patients undergoing standing surgeries. In 
mares, undergoing a standing flank laparotomy for ovariectomy and oophorectomy, detomidine (0.02 
mg kg-1) provided better analgesia than the combination of xylazine and morphine (Jochle et al. 1991).  
The efficacy of alpha2-agonists in managing surgical pain has also been described in small 
animals (Sinclair 2003; Beckman 2013). In dogs, medetomidine alone (0.01, 0.03, 0.09, 0.18 mg kg-
1) has been described to provide similar analgesic effect to xylazine (2.2 mg kg-1) in response to the 
application of superficial pain stimuli (Vainio et al. 1989). Another study has demonstrated that, in 
this species, medetomidine (0.04 and 0.08 mg kg-1) alone provided analgesia for only a minimally 
invasive procedure (Kramer et al. 1996) 
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Dexmedetomidine has been compared to morphine for the management of postoperative 
analgesia in dogs undergoing abdominal or thoracic surgery, or spinal neurosurgery (Valtolina et al. 
2009). In that study, dogs receiving dexmedetomidine (0.001 mg kg-1 followed by an infusion of 
0.001 mg kg-1 h-1) or morphine (0.1 mg kg-1 followed by 0.1 mg kg-1h-1) had similar pain scores during 
the first 12 hours after surgery even if more dogs receiving dexmedetomidine required rescue 
analgesia (11/20) as compared with those treated with morphine (8/20) (Valtolina et al. 2009).  
In dogs, the combination of dexmedetomidine with morphine or methadone has been 
demonstrated to be more effective than dexmedetomidine alone (0.01 mg kg-1) in suppressing the 
withdrawal reflex induced by the application of toe pinches (Cardoso et al. 2014).  
Combined alpha2-agonists and opioids also potentiate their analgesic effect in cats. In a study on 
cats, dexmedetomidine (0.020 mg kg-1) combined with buprenorphine (0.010 mg kg-1) significantly 
increased the thermal nociceptive threshold from 0.25 to 1.25 hours after administration (Slingsby et 
al. 2015). This effect was greater than the same doses of buprenorphine or dexmedetomidine 
administered alone. 
 
Local administration 
The local administration of alpha2-agonists has been described for epidural analgesia, local 
infiltration, peripheral nerve block and intraarticular infiltration (Campoy and Read 2013). 
Alpha2-agonists, by means of their action on alpha2A-adrenoceptors, enhance the action of local 
anesthetic drugs (Yoshitomi et al. 2008). In an experimental study on guinea pigs, dexmedetomidine 
has been proven to increase the degree and the duration of the analgesic effects of lidocaine in a dose-
dependent manner when injected intracutaneously. In the same study the improved anesthetic effect 
was reversed by yohimbine (alpha2A, -2B, and -2C adrenoceptor antagonists) but not by prozosin 
(alpha1, alpha2B, and 2C adrenoceptor antagonists) (Yoshitomi et al. 2008). 
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In an experimental study on rats, dexmedetomdine (0.0005, 0.002, 0.006 and 0.02 mg kg-1) was 
added to ropivacaine 0.75% to achieve a sciatic nerve block, and the sensory blockade to the 
application of a heat stimulus was evaluated (Brummet et al. 2009). The addition of dexemdetomdine 
increased the duration of the sensory block in a dose-dependent manner; however, when 
dexmedetomidine was used alone, no significant motor or sensory block was obtained (Brummet et 
al. 2008). At histopathological evaluation, a mild perineural inflammation was recorded 24 hours 
after the experiment; however, no signs of perinaural inflammation were found 14 days later. 
Moreover, the highest dose of dexmedetomidine (0.20 mg kg-1) did not provoke any histological 
nerve damage (Brummet et al. 2009). 
In cats, the combination of dexmedetomidine (0.001 mg kg-1) with bupivacaine (0.46 mg kg-1) 
in achieving a sciatic and femoral nerve block did not decrease the response to toe pinching and did 
not increase the paw withdrawal threshold as compared to bupivacaine administered alone 
(Evangelista et al. 2017). Furthermore, in a previous study on dogs, dexmedetomidine (0.0001 mg 
kg-1) combined with ropivacaine (0.74 mg kg-1) to achieve a sciatic and femoral nerve block did not 
increase the duration of the sensory block (Trein et al. 2017). These results differ from human studies 
which used dexmedetomidine in combination with local anesthetic drugs to perform local anesthetic 
techniques. Marhofer and colleagues (2013) have reported that in human volunteers, 
dexmedetomidine (0.02 mg kg-1) administered with ropivacaine (0.75%) to achieve an ulnar nerve 
block, increased the duration of the sensory block as compared with ropivacaine alone when the 
pinprick test was applied. 
 
Epidurally administered alpha2-agonists exerts their analgesic effect by means of their action at 
the spinal level; however, systemic absorption cannot be excluded (Sabbe et al. 1994; Steagall et al. 
2017). In dogs, epidurally or intrathecally administered dexmedetomidine provided comparable 
antinociceptive effects to systemically administered dexmedetomidine but without any signs of 
sedation (Sabbe et al. 1994). A study has compared the effects of the epidural administration of 
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lidocaine 2% alone or in combination with alpha2-agonists (xylazine 0.25 mg kg-1, romifidine 0.01 
mg kg-1, detomidine 0.03 mg kg-1, dexmedetomidine 0.002 mg kg-1 or clonidine 0.005 mg kg-1) in 
dogs undergoing ovariohysterectomy (Pohl et al. 2012) Among the other alpha2-agonists, xylazine 
has been shown to determine a longer lasting analgesic effect lasting up to 4 hours (Pohl et al. 2012). 
In the same study, 3 out of the forty-two dogs involved which received detomidine, 4 which received 
xylazine and 5 which received clonidine required inhalation anesthesia in addition to the epidural; all 
bitches receiving epidural dexmedetomidine required isoflurane anesthesia.  
In dogs undergoing orthopedic surgery, epidural medetomidine (0.015 mg kg-1) has provided 
analgesia comparable to epidurally administered oxymorphone, but a higher incidence of 
cardiovascular side effects has been recorded. The epidural administration of medetomidine (0.005 
mg kg-1) combined with morphine (0.1 mg kg-1) did not provide any benefit as compared to the use 
of medetomidine alone (Vesal et al. 1996; Pacharinsak et al. 2003).  
In horses, epidural detomidine has frequently been used to provide effective analgesia for 
standing procedures. Epidurally administered detomidine induced analgesia extending from the 
coccyx up to T15 and, as compared to xylazine, induced a higher degree of cardiovascular side effects 
and a more frequent change in hind limb position (Skarda and Muir 1996). When continuous IV or 
epidural detomidine infusions have been compared in mares undergoing standing ovariectomy, no 
significant differences in hormonal responses have been detected. However, mares which had not 
been received the local analgesia had a higher visual analogue scale (VAS) score when more painful 
stimuli were applied (Virgin et al. 2010). 
 
The intraarticular administration of alpha2-agonists has also been described (Soto et al. 2014). In 
dogs undergoing stifle joint surgery, intraarticular administered dexmedetomidine (0.0025 mg kg-1) 
has provided postoperative analgesia comparable to intraarticular administered morphine (0.1 mg kg-
1), lasting up to 6 hours (range 2-10 hours). Dogs treated with the combination of the two drugs did 
not require additional analgesia for up to 10 hours (range 4-14 hours).  
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Cardiovascular effects 
Alpha2-adrenoceptor agonists, by means of their action on alpha2-adrenoeceptors, can 
significantly impair the cardiovascular system. Bradycardia, arrhythmia, decreased cardiac output 
(CO) and increased systemic vascular resistance (SVR) are the most commonly reported alterations 
after alpha2-adrenoceptor agonist administration in dogs, cats and horses among others (England and 
Clarke 1996; Pypendop and Verstegen 1998; Ko et al. 2001; Lamont et al. 2001; Carter et al. 2010). 
In an experimental study, dexmedetomidine (0.0005 mg kg-1min-1) has been demonstrated to 
prevent arrhythmia induced by epinephrine in halothane-anesthetized dogs (Kamibahyashi et al. 
1995). In that study, the authors hypothesized that this anti-arrhythmogenic effect was mediated by 
the action of dexmedetomidine on central imidazole receptors. In fact, the administration of two 
imidazole- alpha2-antagonists inhibited or reversed the dexmedetomidine action while the effect of 
non-imidazole alpha2-antagonists was not significant. 
 
Heart rate 
In several species, the administration of alpha2-agonists has usually been associated with a 
decrease in heart rate (HR) with respect to baseline values (Golden et al. 1998; Pypendop and 
Verstegen 1998; Ko et al. 2001; Lamont et al. 2001; Ilbäck and Stålhandske 2003; Carter et al. 2010). 
In small animals, medetomidine has been reported to induce a significant decrease in HR, and 
some authors have reported that this effect is not dose dependent; at low dosages, the decrease in HR 
is less pronounced and, at higher dosages, it is longer lasting (Pypendop and Verstegen 1998). 
Medetomidine administered by CRI in dogs (0.001-0.003 mg kg-1 min-1), has also been reported to 
decrease the HR (Carter et al. 2010). A decrease in HR has also been reported in cats after 
medetomidine  and romifidine administration, with medetomidine decreasing the HR up to 68% from 
baseline 15 minutes after IM administration (Lamont et al. 2001; Muir and Gadawski 2002). 
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Clonidine, xylazine, detomidine, medetomidine and romifidine are reported to produce profound 
bradycardia and atrioventricular (AV) blocks when administered to horses (Wagner et al. 1991; 
England and Clarke 1996). In equine species, xylazine (1.1 mg kg-1) has been found to induce a less 
profound and a shorter-lasting alteration on HR than that of equipotent doses of detomidine (0.02 mg 
kg-1) and romifidine (0.08 mg kg-1) (Wagner et al. 1991; England et al. 1992).  
 
There are two main mechanisms involved in the reduction of the HR observed after the 
administration of alpha2-adrenoceptor agonists. The interaction of these drugs with the central alpha2-
adrenoceptors reduces the sympathetic outflow, thereby reducing the HR. In addition, the interaction 
with peripheral alpha2-adrenceptors results in increased systemic vascular resistance (SVR) and 
subsequent reflex bradycardia (Sinclair et al. 2003). The direct effects of alpha2-agonists on intrinsic 
myocardial contractility have been excluded in a study carried out regarding the isolated ventricular 
myocardium of ferrets (Housman 1990).  
Preemptive atropine administration has been hypothesized to reduce the incidence of bradycardia 
mediated by alpha2-agonists. However, the increase in HR induced by anticholinergic drugs in the 
presence of a peripheral vasoconstriction due to the alpha2-agonists would increase the risk of 
arrhythmia (Ko et al. 2001). 
 
Arterial blood pressure 
Alpha2-agonist administration is usually characterized by a biphasic pressure response; soon after 
the drug administration, an initial increase in blood pressure is followed by a hypotensive phase 
(Pypendop and Verstegen 1998; Ilbäck and Stålhandske 2003).  
This biphasic pattern has mainly been observed after the administration of higher doses of 
medetomidine (Pypendop and Verstegen 1998). When low doses of medetomidine are administered, 
central effects predominate, and hypotension is more frequently observed. Higher doses of 
medetomidine exert a more pronounced action on peripheral adrenoceptors with subsequent 
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vasoconstriction and a significant increase in arterial blood pressure (Pypendop and Verstegen 1998; 
Ko et al. 2001). However, as the peripheral action ceases, the central effect persists, and the decreased 
CO contributes to the normalization or the decrease of the systemic arterial pressure (SAP) (Carter et 
al. 2010). The hypertensive effect is seen especially after the IV administration of medetomidine; in 
fact, after IM administration, the peak blood concentration is delayed. 
Higher doses of alpha2-agonists can cause a significant increase in blood pressure which can be 
detrimental in patients affected by heart or cardiovascular disease. In a study in dogs, the 
administration of a high dose of medetomidine (0.02 mg kg-1) induced an increase in the SAP up to 
200 mmHg even if of short duration (Pypendop and Verstegen 1998). Medetomidine 0.01 mg kg-1 
given intravenously has been reported to cause sudden cardiac arrest due to the rupture of an aortic 
aneurysm in a dog affected by Spirocerca lupi (Joubert et al. 2005) 
The biphasic response has been described in horses after the administration of clonidine, 
xylazine, detomidine, medetomidine or romifidine (England and Clarke 1996). Detomidine 0.02 mg 
kg-1 IV induced initial hypertension soon after its administration which lasted 15 minutes. This initial 
increase was then followed by a significant decrease in the mean arterial pressure (MAP) with respect 
to the baseline values 1 to 2 hours after administration (Wagner et al. 1991). On the other hand, 
Wagner and colleagues (1991) have observed that xylazine 1.1 mg kg-1 IV and 2.2 mg kg-1 IM 
administered in healthy horses induced a decrease in MAP 5 minutes after administration which 
became statistically significant 15 minutes later and lasted up to 120 minutes.  
Studies in mice have demonstrated that the central hypotensive response after alpha2-agonists 
administration is mediated by the alpha2A-adrenoceptor subtype while the increase in systemic blood 
pressure is mediated by alpha2B-adrenoceptors (Link et al. 1996; MacMillan et al. 1996). In fact, in 
alpha2B-deficient mice, the hypertensive response has not been observed after dexmedetomidine 
administration. On the contrary, the disruption of the alpha2C-subtype did not produce any 
hemodynamic changes with respect to the control animals (Link et al. 1996). In mice with a mutation 
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of the alpha2A-subtype, the hypotensive response was lost after the administration of an alpha2-agonist 
(MacMillan et al. 1996). 
Data concerning the effect of alpha2-adrenoceptor agonists on pulmonary circulation are 
controversial, and vary among drugs and species. In the pulmonary vessels, there is a low density of 
alpha2-agonists when compared to the systemic circulation, and neuronal regulation plays a minor 
role in their regulation (Pypendop and Verstegen 1998; Lamont et al. 2001). In small animals, 
medetomidine did not affect the pulmonary vascular resistance index (PVRI) or the mean pulmonary 
arterial pressure (Pypendop and Verstegen 1998; Lamont et al.2001). In horses, detomidine and 
xylazine induced a significant increase in the PVRI (Wagner et al. 1991). Moreover, while xylazine 
did not affect the mean pulmonary arterial pressure, low and high dose detomidine induced a 
significant decrease in the mean pulmonary arterial pressure.  
 
Cardiac output 
The administration of alpha2-adrenoceptor agonists has been reported to induce a transient 
decrease in both cardiac output (CO) and the cardiac index (CI) (England and Clarke 1996; Pypendop 
and Verstegen 1998; Carter et al. 2010). 
The CO is determined by complex and coupled variables, but primarily depends on HR and 
stroke volume (SV). The SV, that is the volume of blood pumped by the heart in each cycle, is 
influenced by preload, afterload, contractility and lusitropic properties (Muir 2015). A study on the 
isolated ventricular papillary muscles of ferrets has demonstrated that dexmedetomidine has no 
intrinsic contractile effects on the myocardium (Housman 1990). There is a discrepancy among 
authors concerning the effect of alpha2-adrenoceptor agonists on SV and the stroke index (SI) in small 
and large animals (Pypendop and Verstegen 1998; Yamashita et al. 2000; Carter et al. 2010). 
However, it is likely that the commonly observed decrease in CO is mainly due to bradycardia or to 
decreased contractility related to reduced sympathetic tone.  
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Stroke Volume decreased in automatically blocked dogs after medetomidine administration (de 
Morais and Muir 1995). In healthy dogs, medetomidine 0.001 mg kg-1induced a significant decrease 
in CO and the CI without significant alterations in the SI. A lesser decrease in the CI index has been 
reported after the administration of low dose medetomidine (Pypendop and Verstegen 1998). In cats, 
medetomidine 0.02 mg kg-1 induced a significant decrease in the CI up to 37% of baseline 15 minutes 
after administration; the value remained at 50% of baseline 30 minutes later (Lamont et al. 2001). In 
horses treated with xylazine or detomidine, the CO was significantly reduced by both drugs 
administered at different dosages; however, detomidine administration (0.02 mg kg-1 IV) was 
associated with a lower CO and CI lasting up to 60 minutes (Wagner et al. 1991). In this latter study, 
the decrease in CO lasted longer than the reduction of the HR. However, in the absence of significant 
alterations in SV or the SI the authors recognized the decrease in HR as the main cause of the 
decreased CO. 
In another study on horses treated with different dosages of medetomidine, detomidine or 
xylazine, the SV decreased from baseline, even if the variation was not statistically significant 
(Yamashita et al. 2000). 
 
  
 37 
Respiratory effects 
The administration of alpha2-agonists alone has been reported to decrease in fR. due to CNS 
depression (Sinclair 2003). Respiratory depression has not always been associated with a significant 
alteration in blood gas tension (Lamont et al. 2001). In healthy dogs, low dose medetomidine (0.005 
and 0.01 mg kg-1) reduced the sensitivity of the response to increased fractional concentration of 
inspired carbon dioxide (FiCO2). This affected the fR, the tidal volume and the minute volume (Lerche 
and Muir 2004). In horses, xylazine (0.01 mg kg-1) induced a significant decrease in the partial arterial 
pressure of oxygen (PaO2) without altering the partial pressure of carbon dioxide in arterial blood 
(PaCO2) (Lavoie et al. 1992a).  
In horses, the sedation provided by alpha2-agonists is commonly associated with head and neck 
dropping. The alteration in head carriage causes an increase in hydrostatic pressure which results in 
nasal mucosa congestion which contributes to increased airway resistance. In addition, these drugs 
provide a relaxation of the nostrils and head dropping which changes the conformation of the thorax 
and of the lungs. Taken together, these factors contribute to alterations in ventilator mechanics 
(Lavoie et al. 1992b). 
In dogs, peripheral cyanosis has commonly been observed after medetomidine administration, 
also in healthy dogs. Sinclair (2003) has suggested that low blood flow through the peripheral 
capillary bed and high oxygen extraction were the main mechanisms inducing a cyanotic mucous 
appearance in alpha2-treated animals.  
Ruminants, and especially sheep among others, are more sensitive to the respiratory depression 
induced by these drugs, even at low doses. Studies have described profound hypoxemia in sheep after 
the administration of xylazine, romifidine, detomidine, medetomidine or dexmedetomidine, despite 
their alpha receptor selectivity, and without a significant increase in PaCO2 (Celly et al. 1997; Kästner 
et al. 2007). On the basis of their results, some authors have hypothesized that the hypoxia was not 
due to hypoventilation, to changes in body position or to the degree of sedation. Celly and colleagues 
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(1997) concluded that the increase in shunt fraction and the alteration of pulmonary mechanics, with 
a subsequent increase in P(A-a)O2 and a decrease in transpulmonary pressure recorded after the 
administration of all the alpha2-agonists tested, were the main causes of hypoxemia (Celly et al. 
1997). The hydrostatic stress, characterized by increased capillary pressure, and protein and 
erythrocyte extravasation was considered to be the main cause of the pulmonary edema and capillary 
congestion observed in dexmedetomidine-treated sheeps (Kastner et al. 2007) 
The degree of respiratory depression induced by alpha2-agonists increases when they are 
combined with other drugs, such as opioids. With these combinations, oxygenation of the patient is 
strongly recommended, especially in critically ill animals.   
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Other effects 
Glycemic effect 
Alpha2-agonists have been reported to increase serum glucose concentration and to decrease 
insulin levels in several species (Feldberg and Symonds 1980; Ambrisko and Hikasa 2002; Restitutti 
et al. 2012). This hyperglycemic effect induced by alpha2-agonists has been reversed with the 
administration of alpha2-antagonists (atipamezole, yohimbine and MK-467) (Maroto et al. 1992; 
Ambrisko and Hikasa 2002; Restitutti et al. 2012). 
Xylazine has been described to induce hyperglycemia in dogs and cats (Feldberg and Symonds 
1980; Ambrisko and Hikasa 2002). In dogs xylazine (1-8 mg kg-1) increased blood glucose dose 
dependently from two hours after IM administration and to a greater extent than medetomidine 
administered at equipotent sedative doses.  In healthy dogs, the effect of medetomidine on glucose 
concentration depends on the dose administered (Ambrisko and Hikasa 2002). Medetomidine, 
administered at 0.01 mg kg-1, did not significantly alter blood glucose levels (Maroto et al. 1992; 
Burton et al. 1997) while higher dosages (0.02-0.08 mg kg-1) induced a significant increase in blood 
glucose (Maroto et al. 1992).  
 In another study, low dose medetomidine (0.005 mg kg-1 IM) also induced a significant increase 
in plasma glucose concentration in healthy dogs and in dogs with insulinomas. In the latter, blood 
glucose increased by 20 mg dL-1 after medetomidine administration (Guedes and Rude 2013).  
The mechanisms of the hyperglycaemic effects of alpha2-agonists has not yet been clarified and 
the receptors involved vary according to species (Maroto et al. 1992; Ambrisko and Hikasa 2002).  
In the pancreas, alpha2-agonists decrease the insulin secretion by their action on alpha2-
adrenoceptors in the beta pancreatic cells. A study on the isolated rat pancreas has shown that alpha2-
agonists decrease insulin release by 80% while alpha1-agonists induce only a slight decrease in insulin 
secretion, up to 25% (Hillaire-Buys et al. 1985; Ambrisko and Hikasa 2002). In healthy dogs, 
medetomidine (0.01-0.08 mg kg-1) and xylazine (1-8 mg kg-1) reduced insulin plasma levels dose 
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independently without significantly altering glucagone levels (Burton et al. 1997; Ambrisko and 
Hikasa 2002). In dogs with insulinomas, medetomidine (0,005 mg kg-1) also decreased plasmatic 
insulin (by 78%) (Guedes and Rude 2013). 
However, the glycemic effect of alpha2-agonists may depend on different mechanisms other than 
the inhibition of insulin secretion and may also involve other receptors. In dogs, the alpha1-antagonist 
prazosin was more effective than yohimbine in antagonizing the glycemic effect of clonidine (Maroto 
et al. 1992). In cattle, clonidine has been reported to increase glucose release from the liver in vitro 
(Gorewit 1980). These studies support the glycogenolytic effect on the liver induced by alpha2-
agonists by means of their affinity for alpha1-adrenoceptors. This explains the higher increase in 
blood glucose observed after xylazine administration as compared to medetomidine (Ambrisko and 
Hikasa 2002). Dexmedetomidine in dogs (0.001 mg kg-1) significantly increased glucose levels only 
120 minutes after IM administration. This delay of the hyperglycemic effect can be explained by the 
lower affinity of dexmedetomidine for the alpha1-adrenoceptors which are involved in the stimulation 
of glycogenosis in the liver (Restitutti et al. 2012). 
Imidazoline receptors may also be involved in the regulation of the glycemic effects of this class 
of drugs. Imidazoline I1 agonists have been reported to regulate the human glucose metabolism 
(Farsang and Kapocsi 1999; Ambrisko and Hikasa 2002).  
 
Diuretic effect 
In several species, alpha2-agonist administration is associated with an increase in diuresis, and 
changes in urine specific gravity, pH, osmolality, creatinine concentration and electrolytic 
concentrations (Thurmon et al. 1978; Trim and Hanson 1986; Burton et al. 1998; Villela et al. 2005). 
The mechanisms of action primarily include a centrally mediated decreased secretion of the 
antidiuretic hormone (ADH) (Reid et al. 1979; Talukder and Hikasa 2009). In addition, the 
antagonism of the renal tubular effect of ADH and the alpha2-agonist mediated cardiocirculatory 
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alterations may contribute to their diuretic effect (Sinclair 2003). The magnitude of the diuretic effect 
is drug dependent and dose dependent. 
In equine species and in cattle, xylazine induced a dose-dependent increase in urinary output 
(Thurmon et al. 1978; Thurmon et al. 1984; Trim and Hanson 1986). In ponies, xylazine 1.1 mg kg-1 
induced a significant increase in urinary output for up to 2 hours with a peak effect between 30 and 
60 minutes after administration. The treatment also induced a significant increase in potassium and 
sodium excretion without affecting their plasma concentrations (Trim and Hanson 1986). In mares, 
xylazine 0.5, 1.0, and 1.5 mg k-1 induced an increase in urinary output up to 1.82, 3.93, and 5.68 ml 
kg-1 h-1, respectively (Thurmon et al. 1984). In cattle, the diuretic effect of xylazine 0.22 mg kg-1 or 
0.44 mg kg-1 lasted up to 5 hours (Thurmon et al. 1978).  
In dogs, both xylazine (0.24; 0.5; 1; 2; 4 mg kg-1) and medetomidine (0.005; 0.01; 0.02; 0.04; 
0.08 mg kg-1) decreased ADH levels and increased urinary production dose dependently, with 
xylazine inducing a greater increase as compared to medetomidine (Talukder and Hikasa 2009). In 
this study, the diuretic effect lasted up to 4 hours after administration. Both drugs also induced a 
significant decrease in creatinine concentration, in osmolality and in the pH of the urine samples. The 
urinary specific gravity decreased in a dose dependent manner with the lowest value recorded one to 
three hours after administration (Talukder and Hikasa 2009).  
The hypertensive response observed after the administration of alpha2-agonists may be involved 
in the diuretic effects; however, studies have highlighted that increased blood pressure alone cannot 
explain the diuretic effects. In dogs, clonidine (0.03 mg kg-1) induced an increase in blood pressure 
and a significant decrease in plasma ADH from 10.9 ± 1.5 to 5.0 ± 1.1 ng ml-1. However, the 
administration of two alpha2-antagonists (piperoxane and phentolamine) resulted in a reversal of the 
pressure response without significant alteration in ADH concentration (Reid et al. 1979).  On the 
contrary, atipamezole and yohimbine were effective in reversing the medetomidine-induced 
inhibition of the ADH release and the diuretic effect of medetomidine in dogs (Talukder et al. 2009). 
The effect of atipamezole in reversing the diuretic effect has been shown to be dose dependent and 
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greater as compared to that of yohimbine, probably because of its affinity for imidazole receptors 
(Talukder et al. 2009).  
In dogs, xylazine and medetomidine administration also induced a significant increase in the 
atrial natriuretic peptide (ANP) (Talukder and Hikasa 2009; Talukder et al. 2009). However, in their 
study, Talukder and colleagues (2009) found exceptionally that atipamezole administration resulted 
in an additional increase in the ANP in a dose-dependent manner as compared to a reversal of the 
diuretic effect induced by medetomidine. Therefore, the atrial natriuretic peptide, released in response 
to atrial distension which, in this study, may have been associated with increased blood pressure, 
seems to be minimally involved in the diuretic effect induced by alpha2-agonists (Talukder et al. 
2009). 
Some authors have suggested not administering alpha2-agonists to patients with urinary 
obstructions and to take into consideration fluid loss when managing critical patients (Daunt and 
Steffey 2002; Sinclair 2003). 
 
Stress response  
Alpha2-agonist administration has been described to reduce the perioperative release of 
catecholamine. In dogs, medetomidine (0.01, 0.02, 0.04, 0.08 mg kg-1) and xylazine (1, 2, 4, 8 mg kg-
1) suppressed NA release in a dose-dependent manner. Medetomidine also reduced  epinephrine 
release dose dependently and with a greater potency than xylazine (Ambrisko and Hikasa 2002). In 
bitches undergoing ovariohysterectomy who were premedicated with medetomidine, the cortisol 
concentration during the surgery was significantly lower than that of bitches which did not receive 
any premedicant drug (Benson et al. 2000). Moreover, the perioperative alpha2-agonist administration 
inhibited the release of cortisol through their imidazoline activity (Ambrisko and Hikasa 2002).  
In another study, comparing the endocrine effects of medetomidine (0.02 mg kg-1) and 
acepromazine (0.05 mg kg-1) in bitches undergoing ovariohysterectomy, medetomidine has been 
 43 
proven to be more effective in decreasing perioperative plasma cathecolamine and cortisol 
concentrations (Väisänen et al. 2002)  
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Alpha2-antagonists 
Alpha2-agonists have the advantage over other anesthetic drugs in that their effects can be 
reversed by the use of specific antagonists (Rankin 2015). The most commonly used antagonists in 
clinical practice are atipamezole, idazoxan, yohimbine and tolazoline, with atipamezole being the 
most selective for alpha2-adrenocepors and tolazoline the least selective. Atipamezole, idazoxan and 
yohimbine have an alpha2:alpha1 affinity ratio of 8526:1, 27:1 and 40:1 respectively (Virtanen et al. 
1989). In an in-vitro study, Schwartz and Clark (1998) have reported that tolazoline had the lowest 
affinity at alpha2A-, alpha2B- and alpha2C-, and alpha2D- adrenoceptor subtypes as compared to 
atipamezole and yohimbine. As compared to yohimbine, atipamezole had a 100-fold affinity in 
alpha2D-adrenoceptor subtypes, with tolazoline having a similar affinity to yohimbine (Schwartz and 
Clark 1998). Due to its high affinity for alpha2-adrenoceptors and imidazoline receptors, atipamezole 
is the drug of choice for the reversal of dexmedetomidine and medetomidine (Virtanen et al. 1989). 
In addition, atipamezole has been used to reverse detomidine in horses (Skarda and Muir 1998; 
Hubbell and Muir 2006; Di Concetto et al. 2007). There is discrepancy among authors concerning 
the dosage of atipamezole required to reverse detomidine in horses, and they have reported that re-
sedation after administration may occur (Di Concetto et al. 2007). 
In in-vitro studies, atipamezole has been demonstrated to lack affinity for beta- adrenoceptors, 
for histamine receptors, muscarinic receptors, gamma-aminobuttyric acid (GABA) receptors, opioid 
receptors and benzodiazepine receptors (Virtanen et al. 1989). 
Side effects, such as hypotension, tachycardia and excitation after antagonist administration, 
have been reported, especially after IV administration (Sinclair 2003). Cardiovascular alterations 
induced by the IM administration of atipamezole in dogs is not clinically significant (Sinclair 2003). 
Atipamezole (0.015 and 0.03 mg kg-1) IV administration in cats receiving dexmedetomidine CRI 
resulted in an 8% and 4% increase in the HR, respectively and in a 39% and 46% decrease in MAP, 
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respectively. In addition to the clinically apparent cardiovascular changes occurring, atipamezole was 
effective in increasing the CO and decreasing the SVR (Martin Flores et al. 2017). 
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New applications of alpha2-agonists  
in veterinary medicine   
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Alpha2-agonists for semen collection 
Alpha2-agonists has been used for pharmacologically induced ejaculation in-copula and ex-
copula in several species (McDonnel and Love 1991; Silinski et al. 2002). Xylazine, detomidine, 
medetomidine and dexmedetomidine are the compounds described to date to be used for this 
application.  
In horses, xylazine produced ejaculation within few minutes after administration without 
erection. McDonnell and Love (1991) have successfully described the use of xylazine (0.7 mg kg-1) 
for semen collection in horses with ejaculatory dysfunction: in a horse with low libido and in a stallion 
with reduced hind limb strength (McDonnell and Love 1991). When xylazine was administered to 
normal stallions, ejaculation was obtained in 27% of them. Among these cases, ejaculation frequency 
was significantly higher when horses were left together with mares compared with trials in which 
horses did not undergo any pre-treatment stimulation (14%) (McDonnell and Love 1991). The adjunct 
of imipramine, a tricyclic antidepressant, to xylazine, induced ejaculation in the 33% of treated horses 
with ejaculates characterized by a higher spermatozoa concentration, higher total number of 
spermatozoa but a lower total volume (McDonnel and Odian 1994).  
Detomidine in combination with butorphanol has been used in a white rhinoceros, to obtain ex-
copula semen collection with poor results (Silinski et al. 2002). In that study various dosages of 
detomidine and butorphanol (total mg 8/4, 8/8, 10/4, 10/8, 14/4 respectively) or saline solution were 
administered randomly up to 24 trials in a single animal. The medications induced a superior and 
longer lasting erection and a higher number of penile contractions compared to saline solution. 
However, seminal fluid was collected only in 25% of medicated trials and in 21% of the control trials. 
In addition, only small amounts of fluids were collected. The overall motility and vitality of the 
spermatozoa in the samples were 60-85% (Silinski et al. 2002). 
In felids, alpha2-agonists have been included in the protocol for semen collection through urethral 
catheterization after pharmacological induction (Ur. Ca.P.I.). The technique was first described by 
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Zambelli and colleagues in tomcats and consisted in the semen collection through urethral 
catheterization after the administration of high dose medetomidine (0,13-0,14 mg kg-1) as an 
alternative to electroejaculation (Zambelli et al. 2007, 2010). In felids, unlike horses, alpha2-agonists 
did not induce erection and ejaculation but enhanced the sperm release into the urethra. The ultra-
sound examination highlighted a dilation in the prostatic urethra after alpha2-agonists administration, 
corresponding to the sperm release into the urethra (Lueders et al. 2012; Kheirkhah et al. 2017). As 
soon as the sperm is released, the urethral catheterization allows the semen collection by means of 
capillarity. The technique allows the collection of good quality semen; this can be preserved by means 
of cryopreservation or it can be used for in vitro fertilization (Zambelli et al. 2008).  
More recently the Ur.Ca.P.I. technique has been described in several wild species using different 
sedative drugs in combination with alpha2-agonists (Lueders et al. 2012; Kheirkhah et al. 2017). 
Lueders has described the application of the Ur.Ca.P.I. protocol in several wild species of felids 
including 14 animals totally: Lions -Panthera leo- (medetomidine 12 mg and ketamine 150 mg), 
Tiger- Panthera tigris- (medetomidine 4 mg and tiletamine-zolazepam 120 mg), African leopard-
Panthera pardus- (medetomidine 2 mg, midazolam 10 mg and butorphanol 15 mg), Snow leopard -
Panthera uncia- (medetomidine 1.5 mg and ketamine 100 mg), Cheetah -Ancinonyx jubatus- 
(Medetomidine 2 mg and Ketamine 80 mg) and Golden cat –Catopuma temmincki- (Medetomidine 
0.8 mg and ketamine 75 mg). In his study, the Ur.Ca.P.I. technique allowed the collection of small 
ejaculate volume free of urine contamination and characterized by high sperm concentrations. Only 
in two of the fourteen animals included the semen collection was not obtained.  In addition, the 
authors used the sperm collected from the Asiatic golden cat to successfully perform an intrauterine 
artificial insemination. In African lions the Ur.Ca.P.I. technique has been applied administering 
medetomidine (12 mg) combined with ketamine (150 mg) (Lueders et al. 2012). In this species the 
urethral catheterization allowed the collection of semen samples characterized by a lower total 
volume and a higher sperm concentration if compared to ejaculates obtained in the same species with 
elettroejaculation, and with a sperm motility higher than 79.5% (Lueders et al. 2012).  
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In some studies, the administration of alpha2-agonists has been reported to cause urine 
contamination. The mechanism of action inducing this effect has not been determined yet but depends 
on the affinity of these drugs for alpha1-adrenoceptors. In cheetahs (Acinonyx jubatus) the 
administration of tiletamine-zolazepam (1.17 ± 0.14 mg kg-1), ketamine (1.17 ± 0.14 mg kg-1) and 
medetomidine (0.012  ± 0.0017  mg kg-1) induced urine contamination when administered to provide 
sedation to perform elettroejaculation. When dexmedetomidine (0.01 ± 0.0017 mg kg-1) was used in 
place of medetomidine with similar doses of tiletamine-zolazepam and ketamine (1.59 ± 0.1 mg kg-1 
for both of them) urine contamination in semen samples was not observed (Marrow et al. 2015). In 
dogs, yohimbine (0.2 mg kg-1) reduced significantly the spermatozoa displacement in the urinary 
bladder if compared to xylazine (Pineda and Dooley 1994). 
 
Alpha1 and alpha2 adrenoceptors have been identified in the urethra in humans and in laboratory 
animals (Michel and Vrydag 2006). Studies in rabbits have demonstrated that these receptors are 
involved in the regulation of the urethral contraction (Ueda et al. 1984). Studies on rat’s vas deferens 
have demonstrated that alpha1-adrenoceptor agonists induce the contractions of the vas deferens 
through stimulation on alpha1A-adrenoceptors subtype (Aboud et al. 1993). Alpha1-adrenoceptors 
seems to be involved mainly in the regulation of erection and ejaculation, while alpha2 seems to be 
involved mainly in the regulation of sexual behaviors (McDonnell and Love 1991).  
The mechanism of action of medetomidine that allows the sperm release into the urethra, as 
described by the Ur.Ca.P.I. technique has not been clarified yet. Authors hypothesized that this effect 
is due to the action of alpha2-agonists on the adrenoceptors in the smooth muscles of vas deferens. 
However, the distribution of alpha adrenoceptor in urethra and vas deferens has not been described 
yet in these species and is the topic of ongoing researches (personal unpublished results).  
High doses of alpha2-agonists increase the duration of the sedative effects but also the incidence 
of cardiovascular side effects. However, in more recent studies, authors have observed that lower 
doses of medetomidine (0,05 mg kg-1) administered to healthy cats for the Ur.Ca.P.I technique 
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allowed the collection of semen characterized by lower quality in terms of volume, sperm 
concentration, percentage of motility and progressive motility (Zambelli et al. 2011; Cunto et al. 
2015).  
Doses of medetomidine used to perform the Ur.Ca.P.I. are higher than those commonly used in 
the clinical practice and significant cardiovascular alterations have already been described after 
administration of lower doses (Sinclair 2003). To the author knowledge there are no studies 
evaluating the hemodynamic alterations induced by high dose medetomidine in cats. 
 
In the study Non-invasive evaluation of the haemodynamic effects of high-dose medetomidine in 
healthy cats for semen collection the hemodynamic alterations induced by medetomidine 0,013 mg 
kg-1 administered to healthy male cats undergoing semen collection using the Ur.Ca.P.I. protocol as 
described by Zambelli and colleagues (2007, 2010) have been investigated. The hemodynamic 
alterations were evaluted based on the clinical examination, on the blood pressure measurements 
using a Doppler device and on the echocardiography. 
 
The study has been published in the Journal of Feline Medicine and Surgery (No 18, 2016; pages: 
337-343). The final draft post refereeing is reported. Changes may have been made on this work since 
it was submitted for publication. 
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Abstract 
Objectives – To non-invasively assess the cardiovascular effects of high dose medetomidine on healthy male 
cats undergoing semen collection.   
Methods – Haemodynamic evaluations were assessed on the basis of clinical examination, systemic arterial 
blood pressure and transthoracic echocardiography. Eight male domestic short hair client-owned cats were 
sedated with a bolus of medetomidine intramuscularly (0.13 mg/kg), and semen collection was performed. A 
second transthoracic echocardiography and systemic arterial blood pressure measurement were carried out 15 
minutes after sedation. At the end of the examination, the patients received an atipamezole bolus (0.3 mg/kg) 
intramuscularly. 
Results–The cats were deeply sedated, relaxed and laterally recumbent during the entire procedure. 
No rhythm abnormalities were observed during the exams and no significant increase in systemic 
arterial blood pressure was recorded. The heart rate dropped from 200 ± 33 to 92 ± 13.1 beats per 
min after sedation. There was a significant increase in left ventricular dimensions and the left atrial 
area. The parameters of left ventricular systolic function were reduced, as were systemic and 
pulmonary cardiac outputs. Peak diastolic wave velocities were significantly reduced while 
isovolumic contraction and relaxation of the left ventricle were prolonged. Aortic valve insufficiency 
was recorded for all cats while mitral valve insufficiency was noticed in five cats. None of the subjects 
developed systolic anterior motion. 
Conclusion and relevance – The protocol allowed to collect good semen samples in healthy cats. However, 
high dose medetomidine induces significant haemodynamic effects on the feline heart, mainly due to a reduced 
heart rate, an increased cardiac preload and impaired systolic function. The animals recovered from the 
anaesthesia after antagonist administration, without showing any clinically relevant consequences.  
 
 
Introduction 
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Medetomidine is a highly selective α2-adrenoreceptive agonist; it is widely used in veterinary 
medicine to induce sedation, analgesia and muscle relaxation.1-3 Medetomidine is used alone or in 
combination with other drugs for minor surgical and interventional procedures and, if used for 
premedication, reduces the amount of drugs necessary to induce and maintain general anaesthesia.1,3 
In clinical practice, the dose used in cats varies from 0.02 to 0.08 mg/kg.1,3 The sedative and analgesic 
effect, their depth and duration are dose dependent and can be completely reversed by using the 
antagonist atipamezole. 2-4 
Alpha-2-adrenoreceptor activation produces effects on the central nervous system, desirable for 
patient anaesthetic control and, at the same time, it also has several cardiovascular effects. Due to 
peripheral arterial vasoconstriction, medetomidine induces responsive bradycardia mediated by 
ventricular baroreceptors. This effect is potentiated by the action of the drug on the central nervous 
system with subsequent reduced sympathetic tone.1-7 Cardiac output (CO) is typically reduced when 
medetomidine is administered in a healthy animal as a consequence of increased systemic vascular 
resistance (SVR) and reflex bradycardia.1,3,4,8  
In dogs, medetomidine is reported to induce some electrocardiographic alterations, such as enhanced 
sinus arrhythmia, sinus bigeminy and atrioventricular blocks.1,3,9 In cats with hypertrophic obstructive 
cardiomyopathy due to the systolic anterior motion (SAM) of the mitral valve, medetomidine is 
reported to reduce the left ventricular outflow tract gradient and to resolve the dynamic stenosis.8  
Alpha-2-adrenoreceptive agonists and medetomidine can also be used for semen collection. In horses, 
erection and ejaculation can be artificially produced by administering xylazine or imipramine.10 In 
cats, medetomidine induces a myorelaxant effect on the deferent duct, leading to sperm ejection and 
the release of spermatozoa within the urethra.11,12 This method of semen collection in the feline is 
feasible and apparently safe; however, the dose of medetomidine needed to produce a good semen 
sample is much higher than the dose reported for anaesthetic and pain management procedures, and 
varies in cats between 0.13 and 0.14 mg/kg.12,13 The cardiovascular effect of such a dose of 
medetomidine in a population of feline patients has never been evaluated.  
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The aim of the present study was to non-invasively assess the cardiac and vascular sequelae of high 
dose medetomidine in a group of healthy male cats undergoing semen collection.  
 
Materials and methods  
Animals 
Privately owned intact male cats undergoing semen collection at the small animal reproduction 
service of the Veterinary Teaching Hospital were used for the study. All the owners were informed 
about the study and were asked to sign a written informed consent form. The experiment was 
conducted in accordance with the provisions of European Economic Community Council Directive 
86/609, adopted by the Italian Government (D.L. 27/01/1992 n° 116). The study was approved by the 
local and national ethical committees (SVC 43/2013).  
All the animals underwent a complete clinical examination by an anesthetist and a cardiologist in 
order to exclude cats having major systemic abnormalities or cardiac murmurs. The patients were 
included if no clinical signs (gastrointestinal, neurological, respiratory or cardiovascular disorders) 
were detected. Thus, all the animals needed to be classified as I according to the American Society 
of Anesthesiologists’ (ASA) classification of physical status. The patients were hospitalized for the 
time required by the procedure and until complete recovery from sedation. At the end of the protocol, 
all the animals underwent a second clinical examination, and were dismissed in accordance with the 
judgment of the anesthetist. 
 
Sedation protocol and semen collection 
Each patient received a single bolus of medetomidine (0.13 mg/kg; Sedastart, ESTEVE S.p.A) 
intramuscularly (IM) and was placed into a cat carrier sheltered from light and noise but strictly 
monitored in order to evaluate sedation status and possible side effects. After 15 mins, the patients 
were taken out of the carriers and cardiovascular examination was performed as described below. 
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When all the procedures were completed, semen collection was done by Urethral Catheterization 
After Pharmacological Induction (UR.C.A.P.I.), as previously described;12,13 the semen collection 
required approximately 5 minutes. During the entire procedure, the cats received oxygen 
supplementation through an anaesthesia mask. At the end of the examination, the patients received 
an atipamezole bolus (0.3 mg/kg IM, Sedastop, ESTEVE S.p.A,). After 10 mins from the injection 
of the antagonist the grade of sedation and the heart rate were evaluated.  
After animal sedation, the entire procedure took approximately 30 minutes. 
Cardiovascular examination 
Haemodynamic evaluations, assessed on the basis of clinical examination (femoral pulse evaluation, 
mucous membranes and capillary refill time), systolic arterial pressure (SAP) and transthoracic 
echocardiography were carried out before sedation with awake, manually restrained cats, and then 
repeated 15 mins after medetomidine administration. 
Systolic arterial blood pressure was measured using a Doppler device (Minidrop ES-100 VX, 
Hadeco) as reported by Binns et al.14 In detail, the Doppler probe was placed over the common digital 
branch of the radial artery on the palmar aspect of the foot. The hair was clipped before placing the 
probe. Ultrasound transmission gel (Aquasonic 100, Parker Laboratories, INC.) was placed between 
the probe and the skin to improve ultrasonic contact, and the volume of the Doppler machine was 
adjusted to obtain a clearly audible signal. The cuff was inflated until flow sounds were no longer 
audible, and then gradually deflated until clear flow sounds became audible. The manometer reading 
at the reappearance of flow sounds was recorded as the SAP as described by Jepson et al.15 Five 
repeated measurements were carried out; the highest and the lowest values were excluded, and the 
mean value was calculated. 
Transthoracic echocardiography was performed by the same experienced operator (MBT) using an 
ultrasound unit (M7Vet ultrasound unit, Shenzhen Mindray Bio-Medical electronics Co.) equipped 
with a multifrequency phased array probe using second harmonic settings (7-3 MHz) and continuous 
ECG tracing. All echocardiographic examinations were carried out with the cats in both right and left 
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lateral recumbency, using a dedicated table, and following a standard approach as described 
elsewhere.16 Complete M-Mode, 2-dimensional, color, pulsed wave and continuous wave Doppler 
analysis were carried out. The images and videoclips were stored in the internal hard disk memory of 
the ultrasound unit and used subsequently for off-line analysis. The echocardiographic variables 
measured and calculated for this study are listed in Table 1. All the measurement criteria and the 
formulae used to calculate some variables were obtained from the veterinary literature and are 
detailed elsewhere.17 
Statistical analysis 
Data are reported as means and SD. Descriptive statistical analyses were carried out using a 
commercial software program (Microsoft Excel, Microsoft Corporation). Continuous data were tested 
for normality using a D’Agostino-Pearson test. Haemodynamic variables before and after 
medetomidine administration were compared using a paired t test for repeated measurements. P<0.05 
was considered significant. This part of the analysis was run using dedicated software (Prism 5, 
GraphPad Software Inc.). 
 
Results 
Animals and sedation 
Eight cats were enrolled in the study on the basis of the above-mentioned criteria. All animals were domestic 
short hair cats.with an age ranging from 6 to 96 months and having a mean body weight of 3.6 ± 0.9 kg. 
All patients vomited gastric secretions once within 15 mins after medetomidine injection. All the cats were 
deeply sedated, relaxed and laterally recumbent during the entire procedure. Semen collection was feasible in 
all animals. Atipamezole administration produced a visible decrease in the quality of sedation within 10 mins 
after injection; sternal recumbency was achieved within 20 mins in all cats, and complete recovery without 
any grade of sedation was recorded; the discharge was possible not more than one hour after the end of the 
procedure. The owners did not notice any abnormalities at home.  
Cardiovascular examination 
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Arterial blood pressure and echocardiographic examination were performed before and after sedation 
in all cats. No rhythm abnormalities were observed during the exams. All the recorded haemodynamic 
variables are listed in Table 1. Variables with a statistical difference before and after sedation are 
indicated. Heart rates dropped significantly from 200 to 92 bpm (as a mean value) (P<0.01) after 
medetomidine administration. Systolic arterial pressure increased after medetomidine administration, 
but the difference was not statistically significant. Preload increased, as expressed by increased left 
ventricular diastolic dimensions and atrial area, while left ventricular systolic function, and its related 
variables, including CO, appeared reduced due to the medetomidine effect (Fig 1). Some diastolic 
variables, such as E wave, representing the peak velocity of the early left ventricular diastolic refill 
wave, and A wave, the peak velocity of the late left ventricular refill wave due to active atrial 
contraction, and isovolumic relaxation time (IVRT) were also affected in terms of reduction of the 
first two and an increase in the last one. Left ventricular wall thickness and great vessel diameter did 
not change before and after sedation. Only left ventricular posterior wall (LVPWs) thickness in 
systole decreased after sedation. Interestingly, aortic valve insufficiency was recorded for all cats 
while mitral valve insufficiency was noticed in 5 out of 8 cats as an effect of the medetomidine. None 
of the subjects developed SAM. 
 
Discussion 
In the present study, we echocardiographically evaluated the haemodynamic effects of high dose 
medetomidine in healthy cats undergoing semen collection using UR.C.A.P.I.12,13  
The main finding observed was that high dose medetomidine induces significant haemodynamic 
effects on the feline heart. 
The semen collection using UR.C.A.P.I did not produce any pain to cats. The introduction of a urinary 
3F tomcat catheter (Portex Jackson Cat Catheter, Jorgensen Laboratories) in the urethra for semen 
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collection did non evoke any response in cats and changes in cardiac or respiratory frequency were 
not recorded. 12 
The procedure was feasible in all animals, and the patients recovered within 30 minutes after the end 
of the protocol, and only vomiting was observed as adverse effect. However, several haemodynamic 
parameters, as assessed by transthoracic echocardiography, changed significantly after sedation, 
leading to a reduced heart rate (HR), increased preload and reduced systolic function of the left 
ventricle (LV). As an expression of this, CO also decreased significantly after sedation, mainly due 
to the reduction in HR. 
Some of these findings have previously been described in cats receiving low doses (0.02 mg/kg) of 
medetomidine.4 Cardiac output tends to be reduced by 50 to 70% from the starting values, both due 
to the bradycardia effect and suppressed myocardial contractility. This degree of reduction is similar 
between our study and previous studies where lower doses of medetomidine were tested.2,4 Systemic 
blood pressure tended to increase in our study, but no statistical difference was observed. In previous 
studies, the SAP did not show any relevant variation during the first 15 mins after administering the 
medetomidine, but there was a progressive decrease later on.4,18 In the study of Lamont et al.,4 only 
mean and diastolic systemic pressure increased 15 mins after drug administration. In our study, we 
were only able to measure the systolic values using a Doppler device; therefore, our accuracy in 
detecting pressure variations during monitoring could have been underpowered. In fact Jepson et al15 
found that the Doppler device in cats yields superior results than an oscillometric machine for 
determination of systolic blood pressure only, while the determination of the diastolic blood pressure 
is not reliable and more difficult to obtain.  
Systolic function of the LV as assessed by fractional shortening (FS), ejection fraction (EF), end 
systolic volume (ESV), left ventricular internal diameter in systole (LVIDs), and forward aortic and 
pulmonary flows (VTIs) were significantly reduced in the cats in the present study after 
medetomidine was administered. These parameters are not HR dependent as is CO, and their 
reduction represents clear evidence of suppressed systolic function and therefore likely reduced 
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contractility of the ventricle. The clearest explanation for this is the abrupt increase in systemic 
vascular resistance mediated by the medication, which induced an increase in afterload and 
subsequent depressed contractility due to a baroreceptor reflex.8 
On the other hand, in our cats, a significantly increased pre-load was found in response to the 
medetomidine administration. Both left ventricular and atrial dimensions increased, as seen by 
increased LV internal diameter and volume in diastole (LVIDd and EDV) and increased left atrium 
(LA) area. Lamont et al 4 recorded an increase in pulmonary capillary wedge pressure (PCWP) in 
cats sedated with medetomidine. Similarly, Pypendop and Verstegen  reported a transient increase in 
PCPW in dogs after intravenous (IV) administration of medetomidine, and this effect appeared to be 
dose dependent.5 Since PCPW approximates LV preload, a possible explanation for this finding could 
be a transient response to an acute circulatory stasis related to bradycardia and to an increased LV 
afterload, resulting in blood stasis in the pulmonary capillaries. Another explanation could be the 
reduction in myocardial compliance secondary to drug-related decreased myocardial perfusion.4,5 
Similarly, an increase in the SAP expressed by an increase in central venous pressure has been 
described in dogs receiving medetomidine as an expression of reduced venous capacitance and CO, 
and subsequent blood stasis on the venous side.5 
Some LV diastolic variables are known to be affected by HR, such as left ventricular ejection time 
(LVET), IVRT, isovolumic contraction time (IVCT), and LV inflow waves. This could have affected 
the significance of our results since we found a statistical difference for some of these variables in 
our cohort of cats before and after medetomidine administration. However, in a study conducted on 
healthy cats, the authors concluded that, even if a weak correlation is present between HR and mitral 
valve (MV) E and A wave peak velocity, and IVRT, this effect has only minimal influence on the 
haemodynamic variables, and it is unlikely to produce clinical relevance.19 
Aortic and MV insufficiency were highly prevalent in the cats in our study after sedation. This might 
partially be explained by the increased blood pressure which led to stress on the aortic valve with 
subsequent mild leakage during diastole. On the other hand, the LV dilation could have produced a 
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mitral annulus stretch with the subsequent loss of complete closure of the mitral leaflets during LV 
contraction. 
In our study, the cats were judged to be healthy, and recovered completely after sedation. At the end 
of the study vomiting was the only adverse clinical effect seen after medetomidine administration. 
Vomiting could be a cause of mortality in sedated animals because of aspiration. 
 However, in our cohort, it consisted only of  small quantity of gastric secretions and the mouth was 
inspected to exclude the presence of foreign material. Other relevant clinical disturbances were not 
reported by the anaesthetist and the owners. This suggests that, despite the considerable effect on the 
cardiovascular function we observed, these changes are not clinically relevant and dangerous in 
healthy cats. Moreover similar negative effects on the cardiovascular system have already been 
observed in cats even with conventional doses of medetomidine, meaning that some cardiovascular 
sequelae are intrinsic in the mechanism of action of the molecule and are not necessarily dose related. 
It should however be noted that, in another study conducted on cats, such significant 
echocardiographic changes in heart function were not detected when using a standard dose of 
medetomidine.8 Whether high dose medetomidine might significantly impair the cardiovascular 
system, leading to subtle consequences for the animal, cannot be assessed on the basis of our study. 
Some limitations must be highlighted in the present study. First cats were not re-examined after 
administration of atipamezole to evaluate the presence of residual myocardial damage or 
cardiovascular alterations secondary to medetomidine injection. However cats were judged to be 
clinically normal by the anaesthetist at the time of discharge from the hospital, and owners didn’t 
recognize any abnormality at home. Second, even if cats were considered healthy on the basis of 
baseline cardiovascular examination, a subtle myocardial alteration could not be excluded for sure, 
since some cardiomyopathies in cats might be missed until they produce hemodynamic sequelae. 
Third, LV volumes were calculated using also the Teicholz formula, that has not been validated in 
cats, while other 2-dimensional values might be more appropriate in this specie.20 However, Teicholz 
method was just used as an arbitrary way to evaluate the drug induced cardiovascular alterations in 
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the cats of the present study; and these alterations remained statistically relevant even when using 
different techniques to measure CO (i.e. Doppler derived SV) or just measuring the LV diameters 
during systole and diastole. Finally, one single dose of medetomidine was used. This was done since 
the purpose of our study was to evaluate this specific sedative protocol that has been standardized in 
previous studies as a method for semen collection in cats.12,13 
The cats used in the present study were judged to be healthy on the basis of a clinical examination 
and baseline echocardiography. The medetomidine dose used seemed to be well tolerated. However, 
it cannot be ruled out that a significant negative effect on cardiac function might be produced in cats 
with heart disease. A careful cardiovascular examination and echocardiography should be carried out 
before sedation with high dose of medetomidine.  
Conclusion  
 In the present study, the cardiovascular effects of high dose medetomidine (0.13 mg/kg) in intact 
male cats undergoing semen collection were evaluated non-invasively. Significant modification in 
both systolic and diastolic cardiac function and in the SAP were observed. The animals were stable 
during the procedure and completely recovered from the anaesthesia after antagonist administration. 
Whether this sedative protocol might be harmful in cats affected by heart disease remains to be 
clarified. However, since medetomidine can significantly impair cardiac function, a cardiovascular 
examination and echocardiography should be performed before the procedure and the protocol should 
be reserved to cats assessed as ASA I only. 
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Figure 1. Echocardiographic images of two cats enrolled in the study before (left panels) and after 
(right panels) the intramuscular administration of high dose medetomidine (0.13 mg kg-1) for sperm 
collection. In the upper panels, a 2-dimensional guided M-mode analysis of the left ventricular 
function over time obtained from one cat enrolled in the study is displayed . Note the ventricular 
diameter before (a) and after (b) medetomidine administration. There is a clear decrease in heart rate 
and an increase in both diastolic and systolic dimensions with a subsequent reduction in systolic 
function. In the bottom panels 2-dimensional images of the heart base and left atrium (asterisk) of 
another cat enrolled in the study group are shown. An obvious difference in the left atrial area is 
visible between the baseline state (c) and after sedation (d).  
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Baseline Under sedation P value 
Heart rate (bpm) 200±33 91.6±13.1 p<0.001 
Systolic blood pressure (mmHg) 136±12 150±25 p=0.216 
 
   
M-mode derived variables    
   IVSd (mm) 3.9±0.3 4.1±0.7 p=0.562 
   LVIDd (mm) 14.1±1.2 15.3±1.9 p=0.024 
   LVPWd (mm) 3.9±0.5 3.8±0.7 p=0.695 
   IVSs (mm) 6.2±0.9 5.2±1.0 p=0.106 
   LVIDs (mm) 7.3±0.6 11.1±1.9 p<0.001 
   LVPWs (mm) 6.4±0.8 5.2±0.8 p=0.001 
   FS (%) 47.9±3.7 27.6±7.1 p<0.001 
   EF (%) 82.3±2.9 56.8±10.8 p<0.001 
   EDV (ml) 5.2±1.2 6.6±2.1 p=0.022 
   ESV (ml) 0.9±0.2 2.9±1.2 p<0.001 
   SV (ml) 4.3±1.0 3.7±1.2 p=0.055 
   CO LV (L/min) 0.9±0.3 0.3±0.1 p<0.001 
    
Doppler derived variables    
   Aortic velocity (cm/sec) 102.9±24.8 65.2±12.6 p=0.001 
   Aortic VTI (cm) 8.7±1.6 7.8±1.2 p=0.073 
   Aortic diameter (mm) 8.2±1,3 8.2±0.8 p=0.896 
   Aortic CSA (cm2) 2.1±0.7 2.1±0.4 p=1.000 
   SV LV (ml) 1.9±0.7 1.7±0.5 p=0.270 
   CO LV (L/min) 0.4±0.1 0.2±0.04 p<0.001 
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   LVET (msec) 126.5±20.8 175±11.8 p=0.002 
   Pulmonic valve VTI (cm) 10.0±1.4 6.5±1.4 p=0.001 
   Pulmonic valve diameter (mm) 7.3±0.9 7.8±1.0 p=0.055 
   Pulmonic valve CSA (cm2) 1.7±0.4 2.0±0.5 p=0.081 
   SV RV (ml) 1.7±0.5 1.3±0.5 p=0.002 
   CO RV (L/min) 0.3±0.1 0.1±0.03 p<0.001 
   MV E wave peak velocity (cm/sec) 82.0±16.5 54.0±16.8 p=0.002 
   MV A wave peak velocity (cm/sec) 70.8±22.5 31.6±6.4 p=0.003 
   MV VTI (cm) 6.7±0.7 7.1±0.6 p=0.254 
   E wave DT (msec) 65.4±12.6 76.5±21.7 p=0.222 
   E:A 1.2±0.3 1.8±0.7 p=0.117 
   IVRT (msec) 34.9±7.8 70.1±7.5 p<0.001 
   IVCT (msec) 23.1±10.7 53.0±12.8 p<0.001 
    
 LA diameter (mm)   11.3±1.2  12.0±1.6 p=0.262 
 LA area (mm2)   17.7±2.9     21.4±5.0 p=0.029 
 LA:Ao   1.4±0.3    1.5±0.1 p=0.620 
 
   
Presence of SAM 0/8 0/8  
Presence of aortic insufficiency 0/8 8/8  
Presence of mitral valve insufficiency 0/8 5/8  
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Table 1: Haemodynamic variables in 8 male cats sedated with high dose medetomidine (mean±SD). Ao: aorta; 
CO: cardiac output; CSA: cross sectional area; DT: deceleration time; EF: ejection fraction; EDV: end-
diastolic volume; ESV: end-systolic volume; FS: fractional shortening; IVCT: isovolumic contraction time; 
IVRT: isovolumic relaxation time; IVSd: interventricular septal thickness in diastole; IVSs: interventricular 
septal thickness in systole; LA: left atrium; LV: left ventricle; LVET: left ventricular ejection time; LVIDd: 
left ventricular internal diameter in diastole; LVIDs: left ventricular internal diameter in systole; LVPWd: left 
ventricular posterior wall thickness in diastole; LVPWs: left ventricular posterior wall thickness in systole; 
MV: mitral valve; RV: right ventricle; SAM: systolic anterior motion of the mitral valve; SV: stroke volume; 
VTI: velocity time integral. 
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Dexmedetomidine infusion during surgery in two dogs undergoing 
adrenalectomy for a suspicion of a pheochromocytoma 
 
Introduction 
Pheochromocytoma (PHEO), as defined by the World Health Organization (WHO), is a rare 
tumor originating from the chromaffin cells of the adrenal medulla and, in dogs, it accounts for up to 
0.1% of all canine tumors (Reusch 2015). Chromaffin cells are involved in the production and storage 
of dopamine, norepinephrine and epinephrine which are released with the concurrent activation of 
the sympathetic nervous system (Reusch 2015).  
The embryological origin of the chromaffin cells is similar to that of the sympathetic post-
ganglionic neurons: chromaffin cells are modified sympathetic neurons which synthetize, store and 
secrete catecholamines upon stimulation. Both adrenergic and noradrenergic chromaffin cells have 
been identified; these cells, on the basis of the stimulus, secrete epinephrine or norepinephrine. 
Authors have hypothesized the existence of a feedback mechanism regulating the catecholamine 
release, similar to that of sympathetic neurons. In a study using alpha2-knock-out mice, authors have 
found that alpha2A-deficent mice had higher norepinephrine concentrations while alpha2C-deficent 
mice had higher adrenaline concentrations (Brede et al. 2003). Therefore, the authors identified 
alpha2C as the main adrenoceptor subtype involved in the regulation of epinephrine release in the 
adrenal medulla (Brede et al. 2003). In addition, only the mRNA of the alpha2C-adrenoceptor subtype 
has been identified in isolated chromaffin cells from Wild Type mice (Brede et al. 2003). Similarly, 
in the adrenal glands isolated from mice, the alpha2C- has been identified as the main adrenoceptor 
subtype involved in the regulation of the feedback inhibition of the epinephrine secretion by the 
adrenal gland (Moura et al. 2006). In the same study, the authors have demonstrated that 
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medetomidine reduced the outflow of epinephrine and norepinephrine in a concentration dependent 
manner (Moura et al. 2006).  
Imidazole receptors may also be involved in the regulation of catecholamine release from the 
adrenal glands. In isolated bovine adrenal glands, the imidazole alpha2-agonist clonidine inhibited 
concentration dependently the catecholamine secretion induced by carbacol, an acetylcholine 
synthetic agonist; the administration of non-imidazole alpha2-antagonists did not have any effect on 
the secretion of catecholamine induced by the carbacol (Powis and Baker 1986). In a similar study 
regarding isolated bovine chromaffin cells, imidazole agonists inhibited the acetylcholine-evoked 
release of catecholamine from the adrenal medulla.  This inhibition was antagonized by alpha2-
antagonists with affinity for imidazole receptors (tolazoline and cimetidine) but not by nonimidazole 
alpha2-antagonists (Ohara-lmaizumi and Kumakura 1992)  
 
In patients with PHEO, neoplastic cells secrete elevated quantities of catecholamines which 
influence blood pressure, heart rate (HR) and the metabolism in human and small animal patients; 
clinical signs are related to the catecholamine release and depend on their frequency of secretion. 
Moreover, the mass effect of the tumor and its invasiveness can influence the clinical presentation 
(Barthez et al. 1997). 
Adrenalectomy is the treatment of choice for PHEO in dogs (Herrera et al. 2008).  However, a 
report regarding this species has recognized the mortality rate to be 11.7% among dogs undergoing 
surgical treatment as a result of cardiovascular complications (Gilson et al. 1994; Barthez et al. 1997).  
In humans, the goal of perioperative stabilization is to block the effects of catecholamine by 
means of the administration of phenoxibenzamine, a non-competitive alpha1-adrenoceptor blocker 
which acts by blocking the response to circulating catecholamines without inhibiting their synthesis 
(Reusch 2015). Its administration helps in reversing the vasoconstriction induced by catecholamines 
and prevents intraoperative pressure fluctuations.  
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In dogs, the administration of phenoxibenzamine for two weeks before surgery increased the 
survival rate with respect to untreated dogs (48% and 13%, respectively) but it was not completely 
effective in reducing the incidence of cardiovascular complication associated with PHEO ablation 
(Herrera et al. 2008). In fact, in the study of Herrera and colleagues, both treated and untreated dogs 
experienced hypertension, hypotension or arrhythmia. Postoperative arrhythmias, disseminated 
intravascular coagulation, acute respiratory distress syndrome or pancreatitis have been reported as 
causes of death even in dogs treated with phenoxybenzamine (Herrera et al. 2008) 
In human medicine, several studies have described the perioperative administration of 
dexmedetomidine for the anesthetic management of patients undergoing PHEO resection, alone or in 
combination with remifentanil (Wong and Cheung 2004; Schumann and Hudcova 2010; Khetarpal 
et al. 2014; Singh and Singh 2014). In a patient with a suspicion of PHEO, dexmedetomidine 0.001 
mg kg-1 infused over a minute suppressed the levels of norepinephrine by 49.42% (Singh and Singh 
2014). Some preclinical studies have also suggested that dexmedetomidine infusion might contribute 
to the maintenance of good hemodynamic stability in these patients (Schumann and Hudcova 2010; 
Khetarpal et al. 2014).  Schumann and Hudcova (2010) have described the anesthetic management 
of a patient with PHEO undergoing a surrenalectomy using a loading dose of dexmedetomidine 
(0.001 mg kg-1) followed by an infusion at 0.0002- 0.0005 mg kg-1h-1. In this case the alpha2-agonist 
prevented significant alteration in HR during mass manipulation as well as preventing fluctuating 
pressure values. In another study, similar doses of dexmedetomidine in combination with sevoflurane 
did not prevent significant increases in blood pressure and HR during mass manipulation but recovery 
from the anesthesia was uneventful (Khetarpal et al. 2014). 
The aim of this study was to describe the perioperative anesthetic management with 
dexmedetomidine infusion in dogs undergoing celiotomy for adrenalectomy for a suspicion of 
pheochromocytoma. 
 
Case 1  
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A 10–year-old mixed breed female dog (weight 7.2 kg) was presented to the Veterinary Teaching 
Hospital of the University of Bologna as it had been vomiting for 10 days.   
On admission, the dog’s heart rate was 160 beats min-1, respiratory rate (fR) was 28 breaths min-
1 and indirect arterial blood pressures measured with an oscillometric device were: 170 (systolic 
arterial pressure-SAP), 90 (diastolic arterial pressure-DAP) and 117 (mean arterial pressure-MAP) 
mmHg. The hemato-biochemical blood profile was within the normal range. 
Ultrasound examination showed a heterogeneous mass (3.5 x 5 cm) which was diagnosed as a 
right adrenal gland increased in volume. An adrenocorticotropic hormone (ACTH) stimulation test 
was negative, and catecholamine plasma concentrations were normal with the exception of 
metanephrine: 156 ng ml-1 (range 5.4-143.1 ng ml-1). Suspicion of a pheochromocytoma was 
hypothesized. 
An exploratory laparotomy was scheduled fifteen days later; in this period, the dog was treated 
with phenoxybenzamine (0.6 mg kg-1, twice daily). Prior to the procedure, the owner was asked to 
sign a written informed consent form permitting the surgical and medical treatment.  
On the day of surgery, the HR was 158 beats min-1, the fR was 24 breaths min-1 and blood pressure 
measured using an oscillometric device was 170 (SAP), 68 (DAP) and 102 (MAP) mmHg. 
Premedication consisted of dexmedetomidine (Dexdomitor, Elanco Animal Health; Greenfield, MA) 
0.001 mg kg-1 administered intramuscularly (IM). The dorsal pedal artery was cannulated 
immediately after premedication of the patient in order to measure invasive blood pressure. Before 
anesthesia induction, the HR was 108 beats min-1 with rhythmic pulse, the fR was 12 breaths min-1 
and the invasive blood pressures was: 140 (SAP), 78 (DAP) and 98 (MAP) mmHg. General 
anesthesia was induced 15 minutes after premedication with propofol (Propofol Kabi, Fresenius Kabi; 
Bad Homburg, Germany) administered intravenously (IV) to effect (2.5 mg kg-1) and, after 
intubation, general anesthesia was maintained with isoflurane (Isoflo, Abbott Laboratories Ltd; 
Chicago, USA) vaporized in 100% oxygen (1 L min-1). The dog was mechanically ventilated in order 
to maintain an end-tidal carbon dioxide partial pressure of 45 ± 5 mmHg.  Dexmedetomidine and 
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remifentanil (Ultiva, GlaxoSmithKline Manufacturing Spa, Parma, Italy) were administered IV via 
continuous infusion at 0.0005 mg kg-1h-1 and 0.0003 mg kg-1min-1, respectively, started at the moment 
of induction. Lactated Ringer’s solution (Ringer lattato, ACME; Reggio Emilia, Italy) (10 mL kg-1h-
1) was administered IV throughout the anesthesia. Constant intraoperative monitoring was carried out 
with fR, an electrocardiogram (lead II), pulse rate and hemoglobin saturation measured using a pulse 
oximeter, measurement of in– and expired gas concentrations, esophageal temperature and invasive 
blood pressures derived from a multiparametric monitor (Datex-Ohmeda- S3; Datex-Ohmeda Inc; 
Madison, USA).  
Total anesthesia time was 160 minutes; the surgical manipulation of the mass lasted 72 minutes. 
An end-tidal isoflurane concentration of 1-1.2%.was necessary to maintain anesthesia throughout the 
surgery. 
At induction, no remarkable hemodynamic changes were recorded. The mean HR for the entire 
period of anesthesia was 86 (range 70-124) beats min-1. The mean arterial pressure was 72 mmHg 
(range 65-85 mmHg) (Figure 1). An increase in HR (124 beats beats min-1) and blood pressure (170 
mmHg SAP, 85 mmHg MAP and 43 mmHg DAP) related to the surgical manipulation of the mass 
were detected. After tumor removal, the blood pressure decreased progressively  up to a SAP of 120 
mmHg. The mean end-tidal carbon dioxide partial pressure was 44 ± 3 (range 41–48) mmHg during 
anesthesia. At the end of the surgery, the isoflurane was discontinued, and the dog regained complete 
consciousness in 25 minutes. After extubation, dexmedetomidine and remifentanil infusions were 
stopped; postoperative analgesia was provided by methadone (Eptadone, Molteni Farmaceutici; 
Florence; Italy) every four hours for three days and then by buprenorphine (Temgesic, RB 
pharmaceuticals Limited; Slough, UK) (0.015 mg kg-1 IM) every 8 hours until the dog was 
discharged. 
The dog was discharged five days later with a histological and immunohistochemical diagnosis 
of adenocarcinoma. 
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Figure 1- Cardiovascular parameters for CASE 1 recorded before sedation, at induction and 
intubation, during mass surgical manipulation (T60-T120) and at the time of extubation (T160): Heart 
rate (HR), systolic arterial pressure (SAP), diastolic arterial pressure (DAP) mean arterial pressure 
(MAP). Dexmedetomidine (0.0005 mg kg-1h-1) and remifentanil (0.0003 mg kg-1min-1) were 
administered by constant rate infusion throughout the anesthesia.   
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Case 2 
A 5–years-old mixed breed male dog (weight 6.4 kg) was presented to the Veterinary Teaching 
Hospital of the University of Bologna with an history of vomiting and diarrhea for six months. The 
ultrasound and the computed tomography (CT) examinations revealed a right adrenal gland increased 
in volume (2.0 x 1.0 cm) and an invasion of the vena cava (1.5 x 1.0 cm). At the first clinical 
evaluation, the pulse rate was 68 bpm; the blood pressure was evaluated with an oscillometric device 
(PetMap) and the following values were recorded: 163 (SAP), 102 (DAP) and 118 MAP. The blood 
chemistry was in the normal range but the urinary Normetanephrine: creatinine ratio was increased 
(201.76; range 25.2-120.1). A suspicion of pheochromocytoma was hypothesized. The dog was 
treated with phenoxybenzamine for three weeks before surgery (adrenalectomy); the therapy induced 
a regression of the gastrointestinal symptoms and a decrease in blood pressure. Prior to the procedure, 
the owner was asked to sign a written informed consent form permitting the surgical and medical 
treatment.  
On the day of surgery, the dog’s HR was 100 beats min-1 and the blood pressure was 121 mmHg 
(SAP), 87 mmHg (DAP) and 96 mmHg (MAP). The patient was premedicated with dexmedetomidine 
0.001 mg kg-1 administered IM. Propofol (4 mg kg-1 IV) was used for induction until endotracheal 
intubation was achieved, and general anesthesia was maintained with isoflurane in oxygen and air 
(50:50). During the procedure, dexmedetomidine (0.0005 mg kg-1h-1) and remifentanil (0.0003 mg 
kg-1 min-1) CRIs were administered starting soon after induction. Lactated Ringer’s solution (10 mL 
kg-1h-1) was administered IV throughout the anesthesia. The intraoperative monitoring was carried 
out with fR, an electrocardiogram (lead II), pulse oximetry (SpO2), measurement of in–and expired 
gas concentrations, esophageal temperature and invasive blood pressure. Total anesthesia time was 
330 minutes; total mass manipulation was 120 minutes and, for the removal of the vena cava invasion, 
the vessel was clamped for 14 minutes. After an abdominal opening, a liver neoformation was 
identified and, in adjunct, a hepatic lobectomy was performed.  
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The induction was smooth without significant hemodynamic alterations (Figure 2). The end-tidal 
isoflurane concentration was set between 0.9 and 1.2 % in order to maintain a stable anesthetic plane. 
During the procedure, the mean HR was 95 beats min-1 (range 78-144) and arrhythmias were never 
recorded. The mass manipulation induced a mild increase in the mean HR (from 93.5 beats min-1 
before mass manipulation to 99.0 beats min-1 during mass manipulation) and in mean MAP (from 
71.8 mmHg before mass manipulation to 73.9 mmHg during mass manipulation). At the moment of 
the vena cava clamping, the MAP dropped to a mean of 61 mmHg (range 50-70 mmHg) and the mean 
HR increased to 121 beats min-1 (range 95-144). The hypotension was dealt with by means of the 
administration of a bolus of Lactated Ringer’s solution (10 ml kg-1). At the end of the procedure, the 
isoflurane was discontinued and the dog was extubated five minutes later; the recovery was 
uneventful with the exception of mild bleeding from the subcutaneous tissues. Soon after extubation, 
the remifentanil and dexmedetomidine infusions were discontinued. Postoperative analgesia was 
provided with lidocaine and fentanyl CRI until the following day and then with methadone (0,1 mg 
kg-1) as needed. The histopathological evaluation revealed a diagnosis of adenocarcinoma. 
The data were elaborated using Microsoft Excel (version 15.27, 2016; Microsoft corporation, 
WA, USA). 
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Figure 2- Cardiovascular parameters for CASE 2 recorded before sedation, at induction and 
intubation, during mass surgical manipulation (T170), during vena cava clamping (T240) and at the 
time of extubation (T340): Heart rate (HR), systolic arterial pressure (SAP), diastolic arterial pressure 
(DAP) mean arterial pressure (MAP). Dexmedetomidine (0.0005 mg kg-1h-1) and remifentanil 
(0.0003 mg kg-1min-1) were administred by constant rate infusion throughout the anesthesia.   
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Discussion 
In the two cases reported, dexmedetomidine along with remifentanil provided satisfactory 
perioperative sedation for the two dogs with suspicion of PHEO and contributed to maintaining a 
stable intraoperative hemodynamic control with transient cardiovascular alterations recorded only 
during mass manipulation. 
In both dogs histological and immunohistochemical evaluations diagnosed an adenocarcinoma. 
Adenocarcinoma of the adrenal cortex and PHEO may coexist (Galeotti and Marcato 2008). The 
diagnosis of PHEO is challenging: clinical signs, clinico-pathological results and data obtained with 
the diagnostic imaging are not helpful. The measurement of the catecholamines level in plasma or 
urine is more useful. At the microscopic evaluation the distinction between a PHEO form an 
adrenocortical tumor may be difficult and the specificity and sensitivity of the immunohistochemical 
markers in dogs have not been evaluated yet (Reusch 2015). In the first case described the dog had 
increased HR and blood pressure, the metanephrine levels were increased and the ACTH stimulation 
test was negative. The second dog included had increased Normetanephrine: creatinine ratio. In 
addition, in both dogs the mass manipulation induced transient increase in HR and blood pressure, as 
commonly described in case of pheochromocytoma. 
During adrenalectomy for PHEO, the mortality and morbidity of patients are still high due to the 
cardiovascular instability which seems to be related to excessive catecholamine activity during mass 
manipulation by the surgeon (Gilson et al. 1994). The major life-threatening complications reported 
which are associated with PHEO ablation are hypertension, hypotension, arrhythmias and pulmonary 
edema. These can arise intraoperatively but also in the postoperative period (Herrera et al. 2008; 
Adams et al. 2015). Wide variations in blood pressure have commonly been described for this type 
of procedure. Sodium nitroprusside is the drug of choice to treat severe hypertension; it is a potent 
vasodilator with rapid onset and short duration of action. However, it can exacerbate the post resection 
hypotension which is commonly reported when catecholamine levels decrease as a consequence of 
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severe blood loss (James 1989). In the study of Gilson and colleagues (1994), four out of the six dogs 
included experienced hypotension which was treated with high volumes of crystalloid fluids. Only 
one dog required an infusion of dobutamine but remained hypotensive at recovery. Among 
arrhythmias, atrial premature contractions, ventricular premature contractions, ventricular 
tachycardia, supraventricular tachycardia and ventricular fibrillation have been recorded (Gilson et 
al. 1994; Herrera et al. 2008; Adams et al. 2015). Of the antiarrhythmic drugs, lidocaine, esmolol and 
magnesium sulfate (MgSO4) have been used. Esmolol is a beta-antagonist with a rapid onset of action 
which is indicated for the treatment of sinus or supraventricular tachycardia (Adams et al. 2015). 
Magnesium sulfate blocks catecholamine release from adrenal medulla and peripheral nerve terminal, 
and also blocks the catecholamine receptors (Minami et al. 2002). It has been used in humans for 
pheochromocytoma ablation as a vasodilator and an antiarrhythmic drug (James 1989). Magnesium 
sulfate has also been used in combination with dexmedetomidine with the aim of decreasing the total 
amount of MgSO4, administered thereby limiting the risk of post resection hypotension (Bryskin and 
Weldon 2010). In that report, however, MgSO4 and dexmedetomidine did not prevent an increase in 
HR and blood pressure during mass manipulation, and additional low doses of fentanyl, esmolol and 
nicardipine were needed (Bryskin and Weldon 2010).  
In the present cases, the average HR and arterial blood pressure were within normal ranges for 
almost all the procedures. Only during surgical mass manipulation did the HR and MAP increase but 
these alterations were time-limited and did not need any additional treatment. In the second case 
described, the vena cava clamping induced a reduction in the venous return with subsequent transient 
hypotension responsive to an IV bolus of crystalloid fluids which resolved after the cessation of the 
clamping.  
In a previous study describing the surgical treatment of pheochromocytoma in dogs, the 
following anesthetic protocols were used: acepromazine and atropine, atropine and oxymorphone, 
atropine, acepromazine and oxymirphone or oxymorphone alone (Gilson et al. 1994). However, in 
this type of procedure, anticholinergic and acepromazine can potentially aggravate the cardiovascular 
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status of the patient; atropine can aggravate arrhythmia, and the vasodilation induced by 
acepromazine could make the treatment of hypotension more difficult (Adams et al.2015). 
In the present study, dexmedetomidine was administered in the perioperative period because of 
its anesthetic sparing effect, its analgesic properties and its modulating effect on catecholamine 
outflow. In dogs, a medium dose of dexmedetomidine administered by CRI (0,0005 mg kg-1 h-1) 
reduced the minimum alveolar concentration (MAC) of isoflurane by 18% as compared to saline-
treated dogs (Pascoe et al. 2006). The same dose of dexmedetomidine did not induce significant 
changes in HR and blood pressure as compared with a control group with the exception of an increase 
in diastolic blood pressure over baseline (Pascoe et al. 2006). In a more recent study, the same dose 
of dexmedetomidine (0,0005 mg kg-1 h-1) administered over 180 by CRI in isoflurane-anesthetized 
dogs has been reported to decrease the HR and the cardiac index (CI) up to 17% (Pascoe 2015). In 
this latter study, the authors postulated that changes in the HR of less than 20% from baseline might 
be a good indicator of minor changes in the CI. In the present study, the CI was not evaluated and 
other drugs administered might have influenced the CI and the HR; in addition  the blood pressure in 
our patients could have been influenced by the mass manipulation. Therefore, this evaluation would 
not be significant as regards the effects of dexmedetomidine on the CO and CI.  
Remifentanil is an ultrashort synthetic pure mu opioid agonist. In dogs, remifentanil 0.0003 mg 
kg-1 min-1 has been proven to produce the maximal isoflurane sparing effect, and its prolonged 
infusion does not prevent a rapid recovery (Michelsen et al. 1996; Monteiro et al. 2010). In these 
studies, the use of dexmedetomidine in combination with remifentanil resulted in a lower fraction of 
expired isoflurane with respect to the MAC reported in dogs (1.28±0.6%) by Steffey and Howland 
(1977). The anesthesia of the first dog was maintained with a fraction of expired isoflurane ranging 
from 1 to 1.2% and, for the second dog, the median fraction of expired isoflurane was 1%. 
 In human medicine, the perioperative administration of dexmedetomidine and remifentanil did 
not prevent the hemodynamic instability associated with surgical mass manipulation (Jung et al. 
2012). In our patients the treatment with phenoxybenzamine, for at least two weeks as suggested for 
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humans in The NANETS Consensus Guideline (Chen et al. 2010), likely contributed to reducing 
perioperative complications.  
In conclusion, dexmedetomidine infusion with remifentanil provided satisfactory perioperative 
sedation and analgesia as well as acceptable intraoperative hemodynamic control for two canine 
patients with a suspicion of pheochromocytoma which received preoperative treatment with 
phenoxybenzamine. Additional studies are needed which would include a larger number of cases in 
order to better evaluate the feasibility and effectiveness of the present anesthetic protocol.  
 
  
 82 
Alpha2-agonists for the perioperative management of anesthesia in 
non-human primates undergoing craniotomy 
 
In human medicine alpha2-agonists have been described as safe and effective adjuncts to 
perioperative anesthetic protocols for patients submitted to neurosurgical procedures (Cormack et al. 
2005; Peng et al 2014).  In these patients the hemodynamic stability is pivotal. In the normal brain, 
cerebral blood flow (CBF) is maintained constant by autoregulation’s mechanisms in front of 
alterations in systemic blood pressure within 50 and 150 mmHg. Hypertension can cause forced 
arteriolar vasodilation with subsequent blood-brain barrier alterations and cerebral edema formation. 
Hypotension, on the other side, with a MAP lower than 40 mmHg, could lead to a decreased CBF 
with subsequent cerebral ischemia and mental impairment (Lassen and Christensen 1976). 
A meta-analysis investigating the application of dexmedetomidine in human patients undergoing 
intracranial surgery had shown that dexmedetomidine administration is associated with less 
perioperative intervention to maintain blood pressure and HR within normal ranges and with less 
perioperative general anaesthetics and opioids requirements (Peng et al. 2014). In a study on human 
patients undergoing craniotomy for tumor removal, dexmedetomidine (0.001 mg kg-1 followed by a 
CRI of 0.0004 mg kg-1h-1) administered together with fentanyl CRI (0.001 mg kg-1 h-1) provided a 
significant higher decrease of intracranial pressure (ICP) compared to those patients that received 
fentanyl alone. In the same study, at the recovery, the Glasgow coma scale improved in patients 
receiving dexmedetomidine and deteriorated in those that did not receive the alpha2-agonist; this 
difference was statistically significant (Soliman et al. 2011). Similarly, Kaushal and colleagues 
(2013) in their study on human patients with intracranial tumors, have reported that dexmedetomidine 
given before induction, reduced the HR by 10.48% and SAP by 16.45% upon intubation. In the 
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control group, instead, in which saline solution was administered before intubation, HR and SAP 
increased by 32% and 10.49 % respectively. 
In animal models, dexmedetomidine has been proven to reduce the CBF (Ganjoo et al. 1998; 
Zornow et al. 1990; Zornow et al. 1992). In healthy dogs, anaesthetized with halothane or isoflurane, 
dexmedetomidine administration reduced the CBF by 30-45%, despite a concurrent increase in 
systemic arterial pressure (mean value 180 mmHg) above limits of autoregulation, and without 
causing significant changes in cerebral metabolic rate for oxygen (Zornow et al. 1990; Karlsson et al. 
1990). In rabbits, dexmedetomidine  either reduced ICP by 30% or prevented a significant increase 
in ICP despite an increased systemic arterial pressure when administered at 0.08 or 0.32 mg kg-1 
respectively) (Zornow et al. 1992). In addition in the same study authors found that also in presence 
of cerebral cryogenic lesions, dexmedetomidine (0.32 mg kg-1) did not increase ICP if compared with 
the placebo treated group (Zornow et al. 1992).  
Alpha2-adrenoceptors have been identified in cerebral microvessels in humans and animal 
models (Harik et al 1981; Ferrari-DiLeo and Potter 1985). Dexmedetomidine, through the activation 
of post-synaptic alpha2-adrenoceptors in the cerebral vessels, increases cerebral vascular resistance 
preventing significant alteration of the CBF (Zornow et al. 1990; Prielipp et al. 2002). In fact, in dogs 
dexmedetomidine decreased significantly the vasodilation induced on cerebral vessels by 
halogenated anesthetics. This effect was prevalent on small or large arterioles and on small venules 
and was independent on the dose of dexmedetomidine administered (Ohata et al. 1999). The action 
of these drugs on alpha2-adrenoceptors in the locus coeruleus also decreased the regional blood flow 
in that area. 
Other advantages provided by alpha2-agonists may be beneficial during anesthesia for 
neurosurgical procedures. In facts, through their sympatholytic effects, alpha2-agonists, reduces the 
catecholamine release and therefore prevents the increase in systemic arterial pressure associated with 
the surgical stimulation or with the intubation (Kaushal et al. 2013; Peng et al. 2014). In addition, 
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alpha2-agonists through their anesthetic sparing effect reduce the amount of general anesthetic, 
contributing in the maintenance of a stable anesthetic plane (Ewing et al. 1993; Pascoe et al. 2006).  
 
Non-human primates are widely used as experimental animal models for neurophysiological 
study because of their resembles to humans. Besides their adaptability in laboratory facility, sedation 
is often required to perform also minimally invasive procedures to facilitate handling and to minimize 
risks for the operator: they can bite and they are potentially a reservoir of zoonotic diseases.  
Ketamine (5-20 mg kg-1) has been used as a sole agent in primates to obtain sedation. However, 
alone it does not provide muscle relaxation but tonic-clonic movements, muscle damage upon 
injection and alteration in food intake have been reported after its administration (Popilskis et al. 
2008). Consecutive administration of ketamine (10 mg kg-1) resulted in a cumulative effect, in 
muscular damage and in increased liver enzymes (Lugo-roman et al. 2010). The combination of 
ketamine with alpha2-agonists has been described in non-human primates by several authors as an 
effective alternative to provide deeper immobilization compared with ketamine alone; in addition the 
effects of alpha2-agonists can be reversed with the administration of atipamezole (Sun et al. 2003; 
Lugo-roman et al. 2010). The concomitant administration of medetomidine (0.05 mg kg-1) allowed a 
reduction in the dose of ketamine (2 mg kg-1) necessary to obtain an effective anesthesia. This 
combination resulted in a lower increase in liver and muscular enzymes compared with ketamine 
administered alone (Lugo-roman et al. 2010). Sun and colleagues (2003) have compared ketamine 
(10 mg kg-1) alone and in combination with medetomidine (K 3.0 mg kg-1 and M 0.15) in Macaca. 
They have described that ketamine together with medetomidine provided a longer lasting (71.22 ± 
7.6 minutes vs 27.81± 2.6 minutes) and more profound sedation if compared with ketamine as a sole 
sedative drug (Sun et al. 2003). In the same study authors administered a similar ratio of the same 
anesthetic combination or ketamine alone IM to rats with the aim to evaluate their effects on tissue. 
They observed that inflammation and necrosis were significantly more severe when ketamine was 
administered alone (Sun et al. 2003).  
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In another study similar dosages of medetomidine and ketamine (M 0.15 mg kg-1 and K 3 mg kg-
1) provided considerable benefits compared with ketamine alone: a greater muscle relaxation and 
deeper sedation with an onset of 3.1± 0.4 minutes (Lee et al. 2010). Animals receiving this anesthetic 
mixture presented a lower HR, than those treated with ketamine, without significant differences in 
blood pressure, in PaCO2 and in PaO2 (Lee et al. 2010). The administration of atipamezole (0.1-0.2 
mg kg-1) resulted in the reverse of the sedative effect with a recovery time of 8.7 ± 1.8 minutes (Lee 
et al. 2010; Ochi et al. 2014). Otherwise, medetomidine administered alone did not provide an 
effective sedation even for minimally-invasive procedures. Medetomidine 0.05, 0.1, 0.15 and 0.2 mg 
kg-1 administered IV in Rhesus macaques induced a deep sedation but characterized by sudden and 
aggressive arousal (Capuano et al. 1999). 
To the author knowledge there are no study describing the administration of an alpha2 agonist by 
CRI in non-human primates undergoing craniotomy. 
In the paper Constant-Rate Infusion of Dexmedetomidine to Manage Thiopental Anesthesia 
during Intracranial Surgery in Cynomolgus Macaques (Macaca fascicularis) the perioperative 
management of Macaca fascicularis undergoing craniotomy for neurophysiological studies with 
dexmedetomidine and thiopental administered by CRI for maintenance of general anaesthesia has 
been described. The paper has been published in the Journal of the American Association for 
Laboratory Animal Science (vol 55 no 6, November 2016) and has been reported here with the 
consensus of the Editor. 
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Cynomolgus monkeys (Macaca fascicularis) are often used as 
animal models in behavioral and biomedical research due to 
their phylogenetic affinity to humans. Chemical restraint and 
anesthesia are often required for the care of these species or for 
the purposes of the research in which they are involved.
The α2-adrenoreceptor agonists are a class of drugs widely 
used to produce sedation, anxiolysis, analgesia, muscle relaxa-
tion, and a sparing effect of injectable and inhalant anesthetics 
in different species.16 Moreover, they play a key role in NHP 
pharmacologic immobilization.4,17,20,21 Various studies have 
demonstrated that medetomidine, a highly selective α2 agonist, 
produced a reliable loss of consciousness in rhesus monkeys 
when used alone or in association with ketamine, midazolam, 
or fentanyl.20
Dexmedetomidine is the dextroisomer of medetomidine for-
mulation and, at half the dose of medetomidine, it produces a 
similar effect.2,8 Studies in human anesthesia for intracranial sur-
gery have shown that dexmedetomidine infusion decreases the 
incidence of cardiocirculatory complications in the perioperative 
period, reduces the requirements of supplemental analgesia, 
and has an analogous analgesic effect to remifentanil.12 In dogs, 
dexmedetomidine infusion has produced a marked reduction 
in cerebral blood flow in healthy animals.22 In rabbits, in the 
presence or absence of cryogenic lesions, dexmedetomidine 
infusion had minimal effects on intracranial pressure.23
Various studies involving dogs have investigated the ef-
fect of dexmedetomidine at constant-rate infusion during 
isoflurane anesthesia.6,10,11 At low doses, dexmedetomidine 
infusion (from 0.1 to 0.5 μg/kg/h) yielded acceptable car-
diopulmonary changes, whereas a rate infusion of 3 μg/
kg/h produced significant cardiorespiratory depression.10,11 
Only 2 studies have investigated the effects of a single dex-
medetomidine bolus in NHP for chemical restraint, and no 
data have been reported regarding constant-rate infusion in 
this species.15,19
We hypothesized that dexmedetomidine infusion in Macaca 
fascicularis undergoing intracranial surgery would provide 
analgesia, cardiocirculatory stability and a sparing effect of 
the thiopental dose necessary for maintaining a satisfactory 
plane of anesthesia. The aim of this study was to evaluate 
cardiocirculatory, respiratory, and anesthetic variables during 
dexmedetomidine infusion and thiopental general anesthesia 
in Macaca undergoing intracranial surgery.
Materials and Methods
Five male cynomolgus macaques (Macaca fascicularis; age, 
5 to 12 y; weight, 3 to 11 kg) were involved in the study. Each 
primate underwent intracranial surgery for the purpose of 
anatomic and physiologic research that was approved by the 
Ethical-Scientific Committee of the University of Bologna and 
authorized by National Competent Authorities in accordance 
with Legislative Decree number 116/92 (enacting Council 
Directive 86/609/ECC). At their arrival, the macaques were 
certified free from herpes B virus, SIV, simian retrovirus, and 
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to Manage Thiopental Anesthesia during 
Intracranial Surgery in Cynomolgus Macaques 
(Macaca fascicularis)
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Macaques (Macaca spp.) are often used as animal models in biomedical research involving a neurosurgical approach. The 
development of new anesthetic techniques is pivotal for these studies. Studies in human anesthesia for intracranial surgery 
have shown that dexmedetomidine infusion reduces the incidence of cardiocirculatory complications in the perioperative 
period, reduces the need for supplemental analgesia, and provides an analgesic effect analogous to that of remifentanil. Data 
regarding the anesthetic effects of dexmedetomidine infusion in NHP including Macaca spp. are currently unavailable. The 
study population comprised 5 healthy cynomolgus macaques (Macaca fascicularis) that underwent intracranial surgery. On 
the day of surgery, the subjects were sedated with intramuscular ketamine (8 mg/kg) and dexmedetomidine (0.02 mg/kg). 
Anesthesia was induced with thiopental (3 mg/kg IV) and maintained by using constant-rate infusion of thiopental (3 mg/
kg/h); analgesia was provided by constant-rate infusion of dexmedetomidine (0.012 mg/kg/h). Atipamezole (0.1 mg/kg IM) was 
administered at the end of the surgical procedure. The median heart rate increased after sedation, reaching its highest level at 
60 min (91.0 ± 6.9 bpm); the highest systolic blood pressure (119.6 ± 10.5 mm Hg) occurred at 75 min. No animal experienced 
respiratory arrest, and all recovered within 6 min after atipamezole administration. In cynomolgus macaques, dexmedeto-
midine constant-rate infusion provided adequate analgesia and stable hemodynamic control. Using dexmedetomidine as an 
adjunct to thiopental-maintained anesthesia may be advantageous in healthy NHP undergoing intracranial surgery.
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limited the possibility of endotracheal intubation because of the 
encumbrance of the palate bar.
If a grip reflex or responses to stimuli were present, a bolus 
of thiopental (2 mg/kg IV) was administered. All these events 
were recorded. In the case of hypotension, defined as systolic 
blood pressure of less than 80 mm Hg, dopamine infusion 
from 5 to 10 μg/kg/min was administered IV. At the end of 
the procedures, atipamezole (0.1 mg/kg IM; Sedastop, Esteve, 
Oudewater, Netherlands) was administered. Time of recovery 
was defined as the time from the end of the procedure and ces-
sation of the thiopental until the animal was able to sit up in 
the cage. To record any possible side effects, such as dysphoria 
and vomiting, the anesthetists observed the macaques until 
they were fully awake.
Statistical analysis. All data are reported as mean ± 1 SD. The 
baseline heart rate, respiratory rate, and systolic blood pressure 
(measured after sedation with dexmedetomidine and ketamine) 
were compared between time points by using the Wilcoxon test 
(paired samples) (MedCalc 6.3, MedCalc Software, Ostend, 
Belgium) A P value of less than 0.05 was considered statisti-
cally significant.
Results
The sedation was smooth, and in 3 to 5 min, all of the cyn-
omolgus macaques were lateral recumbent and unresponsive 
to manipulation. At the evaluation of the sedation score, the 
palpebral reflex was depressed, the menace and grip reflexes 
were lost, and muscle relaxation was good. No animal reacted 
during the positioning of the venous catheter.
The procedure time was 204 ± 121.2 min (mean ± 1 SD), de-
pending on the type of surgery. The cardiovascular parameters 
are summarized in Figure 1. The heart rate increased after seda-
tion increasing to 91 ± 7 bpm at 60 min. During the procedure, 
2 macaques experienced sinus bradyarrhythmia consisting of 
a regular variation of rate associated with respiration. No other 
rhythm abnormalities were detected. The lowest systolic blood 
pressure measured in each animal was the baseline value (93.8 
± 5.7 mm Hg). During surgical manipulation, the highest blood 
pressure was measured at 75 min (119.6 ± 10.5 mm Hg). The 
mean arterial oxygen saturation according to pulse oximetry 
at the first measurement point was 97% and was maintained 
throughout the surgical period. No respiratory arrest occurred; 
the respiratory rate ranged from 18 to 24 breaths per minute. 
During the surgical period, the rectal temperature remained 
stable at approximately 36.5 °C with the aid of a forced-air 
warming blanket. Neither heart rate, blood pressure, mean arte-
rial oxygen saturation, nor rectal temperature differed between 
any time points.
Thiopental was maintained through constant-rate infusion of 
3 mg/kg/h in most of the animals. Only one macaque (at 120 
min after induction) showed a marked grip reflex and response 
to stimulus (gross movement of the legs) in the absence of 
changes in cardiorespiratory parameters. In this case, a thio-
pental bolus (2 mg/kg IV) was administered, and thiopental 
infusion rate was increased to a maximum of 8 mg/kg/h until 
the disappearance of the grip reflex. In the remaining 4 monkeys, 
when there was an unexpected positive response to the grip 
reflex, a thiopental bolus (2 mg/kg IV; 2 times for 3 monkeys) 
was administered, however we did not observe hemodynamic 
or other gross movement associated with any surgical stimulus 
(incision of the skin, craniotomy, manipulation of the meninges). 
The average recovery time from anesthesia after atipamezole 
administration was 6.0 min (range, 4.5 to 7.0 min). All of the 
macaques awoke smoothly, without dysphoria or side effects.
simian T lymphotrophic virus. The animals had never been 
used previously in an experiment. 
The macaques were housed individually in appropriately 
sized cages, and environmental enrichment was provided in 
accordance with standard operating procedures. Twelve hours 
before the surgical procedure, food was withheld but water was 
available free choice. Two of the 5 animals were anesthetized 
to implant 2 metal plates on the skullcap for electrophysiologic 
studies; the remaining 3 macaques underwent craniotomy to 
inoculate anterograde tracers in the white matter of the brain 
for anatomic study.
On the day of the surgery, the macaques received ketamine 
(8 mg/kg IM; Ketavet, Intervet Productions, Latina, Italy) and 
dexmedetomidine (0.02 mg/kg IM; Dexdomitor, Elanco Animal 
Health, Hampshire, United Kingdom) in the gluteal muscles. 
The animals were immobilized for injection by using the re-
tractable rear wall of the cage. Sedation time was defined as 
the time between the intramuscular injection and the moment 
when the animal was laterally recumbent on the floor of the 
cage (time 0). As soon as the macaques became recumbent, the 
clinical sedation score was determined in regard to response to 
firm pressure applied to the digits (grip reflex) and response 
to catheterization of the femoral vein (scored as ‘yes’ or ‘no’). 
The macaques were removed from the cages and carried to the 
operating theater. The left saphenous vein was catheterized by 
using a 22-gauge angiocatheter (Delta Med, Milan, Italy), and 
all monitoring devices were attached before the induction of 
anesthesia. A continuous lead II ECG was obtained by using 
a multiparameter monitor (Cardioline, Milan, Italy), and the 
pulse rate and arterial oxygen saturation were monitored by 
pulse oximetry (probe placed on the first anterior digit). The 
respiratory rate was determined by visually monitoring thoracic 
expansion over 1 min. Body temperature was measured by using 
a rectal temperature probe. Blood pressure was monitored by 
using a Doppler device (Minidrop ES-100 VX, Hadeco, Tokyo, 
Japan).3 In brief, the Doppler probe was placed over the com-
mon digital branch of the metatarsal artery on the dorsal aspect 
of the foot; the width of the cuff was approximately 40% of the 
limb circumference, as described previously.18 A no. 3 cuff was 
used for each animal. The hair was clipped before placing the 
probe. Ultrasound transmission gel (Aquasonic 100, Parker 
Laboratories, Fairfield, NJ) was placed between the probe and 
the skin to improve contact, and the volume of the Doppler 
machine was adjusted to obtain a clearly audible signal. Five 
measurements were performed; the highest and the lowest 
values were excluded, and the mean of the remaining values 
was calculated. All of these values and the presence of the grip 
reflex were recorded at 5-min intervals for the duration of the 
entire procedure. A forced-air warming blanket (Bair Hug-
ger, 3M, Berkshire, United Kingdom) was used to maintain 
physiologic body temperature. After the first monitoring was 
completed, a bolus of thiopental (3 mg/kg IV; Pentothal, Intervet 
Productions) was administered, and infusion (3 mg/kg/h) 
was started by using an infusion pump (Angle syringe pump, 
CRIMO, Forlì-Cesena, Italy). Dexmedetomidine infusion (0.012 
mg/kg/h) and lactated Ringer solution were administered (5 
mL/kg/h) by using a peristaltic pump (B-Braun, Melsugen, 
Germany). Oxygen (2 L/min) was provided through a human 
pediatric facemask. The macaque’s head was placed into the 
stereotaxis instrument, with the animal in the sphinx position. 
The animal was fixed to the stereotaxic frame by means of 
tapered ear bars which fit into the external auditory meatus. 
Adjustable infraorbital clamps, and a vertically adjustable palate 
bar prevented rotation of the skull. The stereotaxic apparatus 
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be administered to reverse the cardiocirculatory side effects 
of dexmedetomidine.7 Another potential explanation for the 
bradycardia is an increase in intracranial pressure consequent to 
the surgical procedure, as has been reported in human patients.1 
However, the bradycardia in our macaques began before the 
intracranial surgical procedure was initiated.
Throughout the intracranial surgery, the systolic blood pres-
sure remained stable, at 93.8 ± 5.7 to 119.6 ± 10.5 mm Hg, in all 
5 macaques. The lowest value was measured at the first time 
point. This finding seems to be in contrast to the biphasic arterial 
pressure (initial hypertension followed by hypotension) due to 
dexmedetomidine injection in dogs.14 The effect in our study 
might be explained by a decrease in central sympathetic tone 
that overcame the peripheral cardiovascular effects.16 None of 
our macaques experienced hypotension, and none received 
dopamine infusion.
In the current study, the respiratory rate showed an initial 
decrease, but the arterial oxygen saturation according to pulse 
oximetry remained within the normal range throughout surgery. 
Pulse oximetry is widely considered the optimal method for 
noninvasive continuous monitoring of the oxygen saturation 
of arterial hemoglobin; however to overcome the limitations of 
this technology, a blood-gas evaluation of the oxygen partial 
pressure should be performed.5 In the present study, the pulse 
oximetry did not drop below 97%, and the wave tracing on 
the monitor remained stable throughout surgery; we therefore 
considered blood-gas analysis to be unnecessary. However 
the anesthetist should evaluate capnography and end-tidal 
CO2 to confirm adequate ventilation. A criticism regarding the 
anesthesia management of these 5 macaques was the inability 
to intubate them due to the position of their heads in the stere-
otaxic apparatus and the lack of blood-gas analysis to control 
the pCO2. During intracranial surgery, monitoring of end-tidal 
CO2 or pCO2 enables detection of hypercapnia. In fact, hyper-
capnia decreases the blood pH, which induces vasodilation in 
the brain and consequently increases cerebral blood flow and 
intracranial pressure.
In small animals, α2-adrenoreceptor agonists typically in-
duce vomiting due to their direct action on the chemoreceptor 
trigger zone.16 Similarly, in NHP, vomiting occurs during the 
perioperative period; therefore, endotracheal intubation is rec-
ommended to avoid aspiration pneumonia, which is a risk even 
in food-fasted animals. However, endotracheal intubation was 
not possible in the current study, due to interference from the 
palate bars of the stereotaxic instrument. Regardless, none of 
the 5 macaques vomited during the perioperative period, nor 
were secretions or foreign materials detected in the mouth at 
the end of the procedure.
Increased intracranial pressure is often a complication of 
intracranial surgery, and anesthetic drugs can exacerbate the 
hemodynamic changes in brain perfusion. We did not evaluate 
intracranial pressure directly, but the surgeons did not report 
any increase in bleeding or tissue edema during the procedure, 
and the anesthetist did not note any dysphoria during recovery. 
Dexmedetomidine reduces cerebral blood flow through α2-
adrenoreceptor–mediated vasoconstriction, and atipamezole 
administration allowed rapid recovery from anesthesia, as has 
previously been reported after the administration of medeto-
midine in NHP.17,21
The current study confirmed that the use of dexmedetomi-
dine infusion in healthy cynomolgus macaques undergoing 
intracranial surgery provided stable sedation and adequate 
analgesia for neurosurgical procedures. Furthermore, our 
findings demonstrated that dexmedetomidine administered 
Discussion
The present study confirmed that dexmedetomidine infu-
sion in cynomolgus macaques undergoing intracranial surgery 
provided sufficient analgesia to maintain an adequate plane of 
anesthesia. The combination of ketamine and dexmedetomidine 
produced effective immobilization with an onset of less than 5 
min in all 5 macaques treated.
In NHP, thiopental constant-rate infusion (15 to 17 mg/kg/h), 
used to maintain general anesthesia, has been reported to pro-
vide satisfactory chemical restraint.13 In the present study, the 
thiopental rate infusion was initially set at 3 mg/kg/h. Only 1 
of the 5 macaques demonstrated a positive grip reflex and gross 
movement in response to surgical stimulus; administration of 
a thiopental bolus (2 mg/kg IV) was insufficient to achieve a 
stable anesthetic plane, so we increased the thiopental infusion 
rate to 8 mg/kg/h. This dosage is still lower than that previ-
ously reported in NHP.13 The choice of the initial thiopental 
infusion rate was justified because, in our experience, previously 
reported infusion rates13 associated with dexmedetomidine led 
to excessively deep sedation. In fact, the contemporary use of 
dexmedetomidine, as reported in small animal anesthesiology 
studies, decreased the intraoperative requirement of the drug 
used for the maintenance of general anesthesia.8,10 Comparison 
with a control group of macaques anesthetized with thiopental 
infusion only might be useful in determining the dosages neces-
sary to maintain anesthesia in the absence of dexmedetomidine 
infusion and in assessing the sparing effect of the sedative drug. 
However, the approved protocol did not include a control group 
and, therefore, the dosages were extrapolated from a previously 
published study.13 
Dexmedetomidine produces bradycardia and initial hy-
pertension, as do other α2-adrenoreceptor agonists.14,15 In the 
present study, assessment of pretreatment baseline values for 
heart rate and blood pressure was infeasible due to risk to 
the handler and the need to minimize stress to the subjects. 
The normal resting heart rate of cynomolgus macaques is be-
tween 100 to 200 bpm.9 After sedation, the first recorded heart 
rate was 68.4 ± 7.4 bpm, whereas the mean heart rate ranged 
from 69.6 to 94.0 bpm during the procedure and therefore can 
be defined as bradycardia when compared with the normal 
values previously reported.9 The bradycardia was due to the 
action of the dexmedetomidine on central and peripheral α2 
adrenoreceptors, as described previously for NHP and in small 
animals.4,16 The bradycardia was accompanied by a respiratory 
sinus arrhythmia, which might have been related to the action 
of dexmedetomidine on central α2-adrenoreceptor agonists, 
with a reduction of sympathetic outflow.16 In the event of 
life-threating bradycardia or arrhythmias, atipamezole should 
Figure 1. Cardiovascular and respiratory parameters recorded from 
sedation (time 0) to the end of a neurosurgical procedure in cynomol-
gus macaques.
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through constant-rate infusion to cynomolgus macaques as an 
adjunct to thiopental-maintained anesthesia provided good 
cardiovascular stability and reduced the dose of thiopental 
necessary for maintaining adequate sedation for neurosurgi-
cal procedures, compared with dosages previously reported.13 
During the perioperative period, the macaques’ hemodynamic 
parameters remained in acceptable clinical ranges in the absence 
of cerebral bleeding or edema. Additional studies to determine 
the effects of dexmedetomidine on the cerebral blood flow and 
associated changes in the intracranial blood pressure of NHP 
are warranted.
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Discussion and conclusion 
 
In the present work, new applications of alpha2-agonists in veterinary medicine have been 
described. 
Alpha2-agonists are widely used in veterinary anesthesia because of their sedative, analgesic, 
myorelaxant and anesthetic sparing effect properties. In addition, because of the widespread 
distribution of the alpha-adrenoceptors their application can be extended to different clinical 
application other than the anesthetic one. The administration of alpha2-agonists to obtain ejaculation 
and semen collection in different species has been reviewed in the present work. In cats the Ur.Ca.P.I. 
protocol was first described by Zambelli and collegues and is based on the administration of high 
dose medetomidine (0.13 mg kg-1) for semen collection. When lower doses of medetomidine (0.05 
mg kg-1) were administered to cats low quality semen samples were collected compared with trials in 
which higher doses were used (0.13 mg kg-1). Further studies are needed to verify the expression of 
alpha-adrenoceptors in the genital tract of male cats and the dose dependent affinity of medetomidine 
for these receptors. This is the topic of ongoing research (unpublished results).  
However, studies have described that even when alpha2-adrenoceptor agonists are administered 
at clinical doses in healthy patients they can induce bradycardia, arrhythmia, decreased CO and blood 
pressure alterations (England and Clarke 1996; Pypendop and Verstegen 1998; Ko et al. 2001; 
Lamont et al. 2001; Carter et al. 2010). These cardiovascular side effects cause concerns among 
veterinary practitioners and commonly limit their administration to healthy animals. We have 
therefore investigated the hemodynamic effects of high dose medetomidine (0.13 mg kg-1) 
administered in healthy cats. In our study significant hemodynamic alterations after medetomidine 
administration were observed. In particular we have observed a significant decrease in HR and in CO 
and significant alteration in diastolic and systolic functions. However, similar echocardiographic 
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alterations had been previously reported even after lower doses of medetomidine (0.02 mg kg-1) 
(Lamont et al. 2001). We can therefore conclude that the hemodynamic effects induced by 
medetomidine are not dose-dependent. 
Besides these significant cardiovascular changes, no clinically significant alterations were 
detected at the recovery; however, in this study healthy cats were included and we can’t foresee if 
high doses medetomidine don’t’ significantly impair the hemodynamic functions in patients with 
cardiovascular diseaseskhet. Therefore, when possible, a complete physical examination and a 
cardiovascular evaluation should be performed before the administration of alpha2-agonists, 
especially if high doses are used.   
Besides the undesirable cardiovascular effects, low doses of alpha2-agonists, by means of their 
action on alpha-adrenoceptors and imidazole receptors, induce cardiovascular, respiratory and 
metabolic alterations that may offer advantages for specific clinical conditions. In facts, in human 
medicine, alpha2-agonists have been described as effective adjuncts to improve the hemodynamic 
stability in patients undergoing specific procedures like pheochromocytoma ablation or neurosurgical 
procedures. In these patients the management of the cardiovascular stability is challenging.  
In particular, during pehochromocytoma ablation, cardiovascular complications are common and 
are due to the catecholamine release during mass manipulation. Dexmedetomidine administration in 
patients with peochromocytoma has been described as an effective adjunct to reduce the 
catecholamines’ levels and to improve the cardiovascular stability (Wong and Cheung 2004; 
Shumann and Hudcova 2010; Khetarpal et al. 2014; Singh and Singh 2014). 
Also in patients undergoing craniotomy the hemodynamic stability is pivotal. The cerebral blood 
flow in healthy patients is maintained constant despite narrow variations in arterial blood pressure 
but outside these ranges, CBF changes proportionally with the blood pressure. Dexmedetomidine, 
through vasoconstriction on cerebral microvessels prevented significant alterations in CBF despite 
concomitant variations in systemic blood pressure above limits of autoregulation (Zornow et al. 1990; 
Karlsson et al. 1990).  
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In the present work, preliminary results describing the use of dexmedetomidine for the anesthetic 
management of veterinary patients undergoing pheochromocytoma ablation and craniotomy have 
been reported in dogs and cynomolgus monkeys respectively. In both cases, dexmedetomidine was 
administered pre-operatively and intraoperatively by CRI. We did not observe any significant 
cardiovascular and neurological complications commonly associated with these procedures (Lassen 
and Christensen 1976; Gilson et al. 1994) In these studies, dexmedetomidine throughout its anesthetic 
and analgesic sparing effect reduced the dose of inhalant or injectable anesthetic agents necessary to 
maintain a stable anesthetic plane and this effect may has contributed in the maintenance of the 
cardiovascular stability. In addition, the decrease of the sympathetic tone and the inhibition of the 
catecholamine release provided by dexmedetomidine is beneficial in these patients. In fact, the 
tracheal intubation or the surgical stimulation may increase the catecholamine release with 
subsequent hypertension which can be detrimental in these situations.  
There are several limits of these studies. First of all, only few animals were included: two dogs 
and five macaca respectively. In addition, in both studies only the non-invasive blood pressure was 
evaluated and in macaca neither the EtCO2 or the PaCO2 and the ICP or the CBF were assessed 
intraoperatively as previously described. Further studies concerning the use of alpha2-agonists for the 
anesthetic management of veterinary patients undergoing pheochromocytoma ablation or craniotomy 
are needed, including more animals and using a complete cardiovascular monitoring. Moreover, the 
feasibility of the same protocols in different species should be evaluate. However, in the studies 
reported here, new application of alpha2-agonists in veterinary patients have been described for the 
first time and these preliminary results support the use of dexmedetomidine as an anesthetic adjunct 
for the intraoperative management of canine patients undergoing pheochromocytoma ablation or for 
cynomolgus monkeys undergoing craniotomy. Due to the potentially significant hemodynamic 
changes induced by alpha2 agonists, when possible, a complete clinical examination should be 
performed before their administration, especially if high doses of alpha2-agonists are administered. 
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